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Abstract 
Stress response involves several mechanisms and mediators that allow individuals to adapt to a 
changing environment. The effects of stress may be adaptive or maladaptive, based on the 
timing and intensity of exposure as well as the individual vulnerability. Indeed, while acute 
stress induces the activation of the hypothalamic pituitary adrenal (HPA) axis to ensure the 
normal homeostasis and mediates adaptive reactions to cope with such challenges, chronic 
stress exposure has detrimental and long-lasting effects on brain functions. Actually, stress 
represents a major susceptibility element for psychiatric disorders and stressful life events are 
among the environmental factors that contribute to the etiology of major depressive disorder 
(MDD). However, there are differences in individual susceptibility to develop stress-related 
disorders, with some person displaying vulnerability to stressful event and others showing 
resistance to the same adversities. Moreover, it has to be considered that exposure to an adverse 
situation may leave a permanent ‘scar’ in the individual, which confer enhanced vulnerability 
for relapse.  
In this context, the overall goal of my studies was to characterize the effects of both chronic 
and acute stressors on adult male rats to better understand the behavioral outcomes of stressful 
events as well as the molecular changes that may sustain the pathologic phenotype emerging as 
a consequence of stress exposure. Furthermore, we investigated if the pharmacological 
treatment with lurasidone, a drug approved by the Food and Drug Administration for the 
treatment of different psychiatric conditions, may modulate the behavioral and molecular 
alterations induced by stress exposure. In particular, lurasidone acts, with high affinity, as 
antagonist of dopamine D2 receptor, serotonin 5-HT2A and 5-HT7 receptors, with moderate 
affinity as antagonist of adrenergic a2Aand a2C and as partial agonist of the HT1A receptors. 
Here, by employing the chronic mild stress (CMS) paradigm to induce a depressive like 
behavior in rodents, we identified two populations of stressed animals: one was susceptible to 
stress whereas the other was resilient to stress, in term of anhedonia. Moreover, independently 
from the vulnerable and resilient phenotype, we found that all stressed rats developed cognitive 
deficits. Among the mechanisms underlying the link between cognitive impairment and MDD, 
we found that the cognitive decline associated with stress exposure may be due to alterations in 
de-novo protein synthesis at synaptic levels.  
Interestingly, we highlighted the ability of the antipsychotic lurasidone to normalize not only 
the anhedonic phenotype, but also the cognitive impairment induced by the CMS paradigm. 
Furthermore, known that the function of the HPA axis is altered in psychiatric disorders, we 
provided evidence for the involvement of lurasidone in counteracting the molecular 
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abnormalities induced by chronic stress on glucocorticoids receptor function and 
responsiveness. Additionally, considering that recently epigenetics have been well 
characterized as potential mechanisms by which environmental factors can lead to the 
development of different psychiatric disorders, we demonstrated that the chronic stress 
exposure had long lasting consequences on the HPA axis activity, by acting as modulators of 
the DNA methylation of key players of the glucocorticoid receptor signaling, and that 
lurasidone was able to counteract such abnormalities, suggesting that some of its long-term 
effects may also be related to epigenetic mechanisms. 
Subsequently, since a high percentage of depressant patients experience relapse after a period 
of recovery, we assessed differences in molecular responsiveness to a challenging event, in 
animals that were originally exposed to a chronic stress paradigm and had received the 
pharmacological treatment. In particular, we highlight the different ability of prefrontal cortex 
and dorsal hippocampus to cope with the new challenge, in terms of neuroplastic mechanisms, 
known to be involved in the adaptation of the brain structures to different demand, including 
environmental challenges. 
In addition, in the field of adaptive response to stress, we demonstrated that a single session of 
acute restraint stress was able to enhance the cognitive performance with a specific temporal 
profile, by inducing the activation of selected brain players involved in neuroplasticity, 
including the immediate early genes and the neurotrophic factor Brain Derived Neurotrophic 
Factor. 
These findings support the fundamental impact of stress exposure during adult life, highlighting 
its critical effect on systems and pathways through which stress can contribute to the 
development of stress related disorders. Furthermore, the ability of lurasidone to counteract 
stress-induced abnormalities provide support to the notion that drugs characterized by a multi 
receptor profile may be effective in counteracting different pathologic alterations and, 
speculatively, suggest that such compounds may hold a powerful indication for the treatment 
of different stress-related disorders. 
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Riassunto 
La risposta allo stress nel nostro organismo richiede l’attivazione di meccanismi molecolari e 
di mediatori che permettono agli individui di adattarsi continuamente ai diversi stimoli esterni 
a cui sono giornalmente esposti. Gli effetti dell’esposizione a stress possono essere sia adattativi 
che mal-adattativi, in base alla durata e all’intensità dell’evento stressante: mentre uno stress 
acuto attiva l’asse ipotalamo-ipofisi surrene (HPA) per garantire una normale omeostasi e per 
regolare le reazioni adattative necessarie ad affrontare situazioni stressanti, l’esposizione a 
stress cronico ha effetti dannosi e duraturi sulle funzioni cerebrali. Infatti, lo stress rappresenta 
uno dei principali fattori di rischio per lo sviluppo di patologie psichiatriche ed è tra i fattori 
ambientali maggiormente coinvolti nell’eziologia della depressione. Tuttavia, vi è una diversa 
suscettibilità tra gli individui nello sviluppare disturbi psichiatrici e le alterazioni dovute a 
prolungati eventi stressanti possono essere fisiologicamente recuperate o possono lasciare dei 
segni permanenti che son in grado di conferire un aumentato rischio di vulnerabilità ad ulteriori 
ricadute.  
In questo lavoro abbiamo quindi voluto caratterizzare l’impatto dell’esposizione a stress su ratti 
maschi adulti, al fine di valutare sia gli effetti a livello comportamentale che i meccanismi 
molecolari coinvolti a livello cerebrale nello sviluppo del fenotipo patologico indotto dallo 
stress cronico durante la vita adulta. Inoltre, abbiamo valutato come il trattamento 
farmacologico con l’antipsicotico di seconda generazione a profilo multi-recettoriale 
lurasidone, approvato dalla Food and Drug Admnistration per il trattamento dei disturbi 
dell’umore, sia in grado di modulare le alterazioni comportamentali e molecolari causate dalla 
prolungata esposizione a stress cronico. Il lurasidone è un antagonista dei recettori D2, 5HT2A 
e 5HT7, agonista dei recettori a2Aand a2C e agonista parziale dei recettori serotoninergici HT1A. 
Utilizzando il paradigma di chronic mild stress, modello animale di depressione convalidato 
per indurre un fenotipo depressivo nei roditori, abbiamo identificato due gruppi di animali 
stressati: uno suscettibile e l’altro resiliente. Inoltre, abbiamo dimostrato che lo sviluppo di 
deficit cognitivi, sintomi caratteristici dei pazienti depressi, è indipendente dal fenotipo 
anedonico, dal momento che sono stati osservati in entrambe le sub-popolazioni di ratti 
stressati. A livello molecolare, tra i meccanismi sottesi allo sviluppo del deterioramento 
cognitivo, abbiamo dimostrato come questi deficit, indotti dallo stress, siano associati ad 
alterazioni nei meccanismi di sintesi proteica a livello sinaptico. Abbiamo inoltre avvalorato le 
proprietà antidepressive del lurasidone come farmaco in grado di curare non solo l’anedonia, 
ma anche i deficit cognitivi e la sua capacità di agire a livello dell’asse HPA, noto sistema 
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deregolato nelle patologie psichiatriche, modulando i meccanismi molecolari alterati dallo 
stress cronico, nella via genomica e non genomica dei recettori dei glucocorticoidi. 
Nel contesto delle patologie psichiatriche, recentemente i meccanismi epigenetici son stati ben 
caratterizzati come potenziali fattori attraverso cui gli stimoli ambientali possono contribuire 
allo sviluppo dei disturbi connessi allo stress. Su queste basi abbiamo quindi indagato e 
mostrato come l’esposizione a stress cronico abbia un effetto permanente e duraturo sull’attività 
dell’asse HPA, in particolare modulando la metilazione del DNA di geni coinvolti nel signaling 
del recettore dei glucocorticoidi, e come il trattamento con lurasidone sia in grado di 
normalizzare queste modificazioni epigenetiche.  
Successivamente, siccome un’elevata percentuale di pazienti depressi presenta recidive dopo 
una completa guarigione, abbiamo evidenziato differenze a livello molecolare nella risposta ad 
un nuovo stress acuto, in seguito a un periodo di washout sia dallo stress che dal trattamento 
con lurasidone. In particolare, abbiamo mostrato una differente capacità della corteccia 
prefrontale e dell’ippocampo dorsale di far fronte ad un nuovo stimolo, in termini di fattori 
neurotrofici, noti per essere coinvolti nell’adattamento delle strutture cerebrali ai diversi 
stimoli, compresi gli eventi esterni stressanti. 
Infine, per valutare la risposta adattativa a stress di breve durata ed intensità, abbiamo 
dimostrato come una singola sessione di stress acuto da immobilizzazione possa migliorare la 
performance cognitiva con uno specifico profilo temporale, tramite l’attivazione di alcuni 
circuiti coinvolti nei meccanismi di neuroplasticità.  
In conclusione, i risultati di questo lavoro supportano l’impatto fondamentale dell’esposizione 
a stress durante la vita adulta, sottolineando che questo abbia un effetto critico su sistemi e 
meccanismi che possono essere alla base dello sviluppo dei disturbi psichiatrici. Inoltre, la 
capacità del trattamento farmacologico con lurasidone di contrastare queste modificazioni 
supporta l’attività multi-recettoriale del farmaco nell’essere efficace nel modulare le differenti 
alterazioni patologiche correlate alla depressione maggiore e ai disturbi legati allo stress. 
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Introduction 
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1.1 What is stress? 
The term stress was borrowed from engineering as a measure of the internal forces acting within 
a deformable body by Hans Selye in the 1930s. He translated this description into biology by 
defining stress as the results of an organism’s failed attempt to respond appropriately to a 
physical challenge (Selye, 1998). This explanation has been elaborated by including 
psychological threats by John Mason (Mason, 1959) and in the traditional psychology definition 
of stress, it occurs when a person perceives the demands of environmental stimuli to be greater 
than their ability to meet, mitigate or alter those demands (Lazarus and Folkman, 1984;Lazarus 
et al., 1985). 
A subsequent view of stress includes the concepts of the allostasis to describe the adaptive 
biological processes that preserve “stability through change” (Sterling P, 1988) and of the 
allostatic load and overload, to refer to the toxic stress effect (Sterling P, 1988;McEwen and 
Stellar, 1993;McEwen, 1998). 
Allostasis is the active process of adapting to daily stressors mediated by cortisol, by the 
autonomic, metabolic and immune systems, that act together to maintain homeostasis 
(McEwen, 2006) and are regulated in a balanced way to preserve stability through changes. 
When allostatic mediators are not turned off or are not produced in a stable manner, they can 
cause unhealthy changes in brain and body, thus leading to the so-called “allostatic load”, that 
refers to the cumulative effect of multiple stressors, with the dysregulation of the homeostatic 
network that involves not shutting off the response efficiently, not turning on an adequate 
response in the first place, or not habituating to the recurrence of the same stressor, thus 
dampening the allostatic response. The strongest dysfunctions of these mechanisms refer to the 
“allostatic overload”, that denotes the results of the excess stress, accompanied by damaging 
behaviors, that lead to the pathology (fig. 1).  
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Fig. 1: Illustration of the normal allostatic response, allostatic load and overload. [From (McEwen, 
2007)] 
 
These concepts apply not only to the body but also to the brain, the key organ of stress 
adaptation that provides to ameliorate physiological dysregulation, playing a fundamental role 
in counteracting or exacerbating allostatic load and overload (McEwen, 2007). Indeed, brain 
healthy or unhealthy neuronal functions contribute to determining whether the response to 
challenges is efficient or dysregulated. 
Stress physiology, from a practical point of view, can be divided into “positive stress”, that 
refers to moderate stress response, regulated by stress mediators that promote adaptation during 
the challenge, being turned on or off when needed; “tolerable stress”, that denotes potentially 
damaging stress response that can even promote protection against future stressors, with 
individual internal and external resources that support the system to limit long-term 
pathophysiological consequences; and “toxic stress” that includes the harmful stress responses 
occurring under conditions of severe adversity, with the lack of internal or external supplies to 
cope (Shonkoff et al., 2009), that lead to chronic physiological dysregulation that promotes 
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diseases (Cohen et al., 2007). Furthermore, these environmental perturbations can be worsened 
by both genetic and epigenetic mechanism that alters the brain circuity reactivity. 
Moreover, the duration is one of the most defining features of a stressor. 
“Acute stressors” are intense and short-term exposures, characterized by the occurrence of a 
specific evoking event. “Daily events”, such as deadlines and arguments, are the minor hassles 
that happen frequently whereas “life events” are time-limited and episodic, and they can have 
long-term consequences depending on the nature of the event. “Traumatic events” are severe 
life incidences that can afflict the physical and/or psychological safety of an individual 
(experiencing violence or abuse, the death of a loved one, natural disaster etc.). Instead, chronic 
stressors are present for a long period of times and are associated with high negative and low 
positive daily events (fig.2) (Epel et al., 2018). Enduring stressors may produce chronic states 
that can lead to the development of mental health problem because of the capability of stress 
hormones (cortisol in human and corticosterone in rodents) to access the brain and impact 
affective processing as well as cognitive functioning (Lupien et al., 2007). Chronic stress act as 
a precipitating factor for many psychiatric conditions, including major depressive disorders 
(MDD) (Hammen, 2005;Cohen et al., 2007) but it is also linked to a high risk to develop several 
pathologies, including cardiovascular diseases and infectious diseases (Cohen et al., 2007). In 
particular, the cost of morbidity associated with mental health conditions exceeds that of any 
other diseases (Whiteford et al., 2013;DALYs and Collaborators, 2016). 
 
 
Fig. 2: Time scale of stressors exposure [From (Epel et al., 2018)]. 
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A hallmark of the stress response is the activation of the autonomic nervous system and of the 
hypothalamic-pituitary-adrenal (HPA) axis, that produce adaptation through “allostasis”. 
The corticotropin-releasing hormone (CRH) and vasopressin are essential for coordinating the 
stress response, by acting on the HPA axis, thus regulating the levels of corticosteroid hormones 
circulating in the blood. In particular, in response to a stressor, neurons in the paraventricular 
nucleus of the hypothalamus secrete the CRH hormone, which induces the synthesis and release 
of the adrenocorticotropic hormone (ACTH) from the anterior pituitary. ACTH then stimulates 
the release of corticosteroids (cortisol in human and corticosterone in rodents) from the adrenal 
glands.  
Corticosteroids in the brain operate through mineralocorticoid (MR) and glucocorticoid (GR) 
receptors, which are co-expressed abundantly in the neurons of limbic structures (Herman et 
al., 2003). MRs have a high affinity for corticosteroids, so they are mostly occupied even when 
circulating corticosteroid levels are low (de Kloet et al., 2005). GRs have tenfold lower affinity; 
consequently, these receptors are only partially bound by corticosteroids under basal conditions 
and become more occupied as corticosteroid levels increase, for example, after stress. 
Both corticosteroids receptors mediate the initiation and the termination of the HPA axis stress 
response, via the negative feedback, and modulate acquisition processing, storage and retrieval 
of stressful experiences (Sapolsky et al., 2000). In particular, endogenous glucocorticoids 
(GCs), in normal physiological circumstances, serve as potent negative regulators of HPA axis 
activity by binding to their receptors in different tissues, including hypothalamus, pituitary and 
hippocampus. However, sustained elevations of GCs may disrupt the negative feedback control 
of the axis, with an excessive activation of the HPA system. 
GR and MR exist in membrane-bound form and nuclear form. Indeed, they mediated non-
genomic mechanisms and genomic mechanisms (fig. 3). Via the membrane-associated 
receptors, GCs can directly stimulate the release of excitatory amino acids and indirectly 
regulate both glutamate and GABA release, through the cross-talk with the endocannabinoid 
system (Hill and McEwen, 2010). Moreover, GCs can also translocate GRs to mitochondria, 
where they regulate mitochondrial oxidation, free radical formation, membrane potential and 
enhance their calcium buffering (Du et al., 2009). 
The genomic mechanism involves both direct interactions with glucocorticoid response element 
(GRE), mediated by cytoplasmic receptors that move to the nucleus and act as transcription 
factors, and indirect action via tethering to other transcription factors (Revollo and Cidlowski, 
2009). 
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Fig. 3: Genomic and non-genomic mechanisms of glucocorticoids receptor [From (McEwen et al., 
2015)]. 
 
The glucocorticoid signaling is a complex homeostatic system that cooperates with other 
network to help the organism to cope with stressful stimuli, in order to adapt to the demand of 
challenging situation (Chrousos and Kino, 2005;Chrousos, 2009;Nicolaides et al., 2015) in a 
non-linear interaction. The glucocorticoid effects within the brain are graphically described by 
the inverted U shape dose-response curve (fig. 4), accordingly with the conceptual work of 
McEwen that suggest that the stress hormones, essential for survival, can have damaging effects 
on the brain if they are secreted over longer periods of time (McEwen and Wingfield, 2003). 
Normal homeostasis is achieved in the central optimal range of the curve, whereas hypofunction 
or hyperfunction of the HPA axis may have short-term or long-term adverse consequences thus 
compromising the well-being and/or the performance (Chrousos, 2009;Charmandari et al., 
2014;McEwen et al., 2015). Indeed, while exposure to glucocorticoids in term of minutes to 
hours, such as happens during an acute stress, was associated with low calcium influx but 
enhanced long-term potentiation (LTP), prolonged periods of stress, associated with high levels 
of GCs circulating, enhanced cellular calcium exposure and impaired LTP functions (Joels and 
de Kloet, 1992;Joels et al., 2003a;Joels et al., 2003b;McEwen et al., 2015). An imbalance 
between MR and GR actions may lead to an altered HPA axis response, thus increasing the 
vulnerability to affective disorders (De Kloet et al., 1998) and corticosteroid receptor function 
has been found to be altered in many patients with major depressive disorders (Holsboer, 2000). 
Polymorphisms of genes encoding for both the receptors have been associated with the 
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disruption of the HPA axis functioning and depression (van West et al., 2006), whereas in mice 
a reduction of GR signaling activated the axis ad impaired cognition (Oitzl et al., 2001;Ridder 
et al., 2005) and the GR deletion increased corticosterone levels and induced depressive-like 
behavior (Tronche et al., 1999;Boyle et al., 2005). 
 
 
Fig. 4: Inverted U shaped curve of glucocorticoid effects in dose and time [From (McEwen et al., 2015)] 
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1.2 Stress resilience 
Although stress is the major risk factor for psychopathologies, there are differences in the 
individuals’ susceptibility to stress (Russo et al., 2012;Duclot and Kabbaj, 2013;McEwen et al., 
2015). Indeed, while some people display a high vulnerability following exposure to stress, 
others show a resistance to its maladaptive effects (Sandi and Richter-Levin, 2009;Russo et al., 
2012). This concept is known as resilience, described by Russo and colleagues as the “capacity 
of an individual to cope negative social, psychological, and biological consequences of extreme 
stress that would otherwise compromise their psychological or physical well-being” (Russo et 
al., 2012). Some reports indicate that resilience in humans represents an active, adaptive 
process, and not simply the absence of pathological responses that occur in more susceptible 
individuals (Charney et al., 2004;Feder et al., 2009). The determinants of resilience involve 
different mediators of the stress response system, including neurotransmitters, neuropeptides, 
hormones, as well as polymorphisms of mineralocorticoid, glucocorticoids and arginine 
vasopressin receptors (Walker et al., 2017). Moreover, life events can modulate the mechanisms 
responsible for the active resilience, including brain neurocircuits and epigenetic processes, 
underlying why stress resilience is not constant during life but may be modified by external 
stimuli (McEwen et al., 2016). Different animal studies have investigated the concept of 
resilience by evaluating the ability to avoid some or all the deleterious behavioral effects of 
chronic stress and the percent of animals exhibiting resilience varies across several stress 
paradigms (Russo et al., 2012). Indeed, resilient animals show some behavioral adaptations that 
appear maladaptive, but they exhibit clear resistance to many others, with respect to the diverse 
chronic stress procedures to which they are exposed (Russo et al., 2012). Actually, there is 
increasing evidence that stress resilience arises from active coping strategies, both behavioral 
and molecular, with some pro-susceptible molecular factors which, if removed, promote stress 
resilience (Tsankova et al., 2006;Christoffel et al., 2011;Christoffel et al., 2012;Anacker et al., 
2016;Anacker et al., 2018). In this field, increasing the knowledge about the neurobiological 
mechanisms that confer resilience on an individual should improve the treatment strategies to 
prevent the risk of stress-related disorders. 
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1.3 Stress and memory 
Stress can profoundly influence what we learn by orchestrating the signaling of various 
hormones, peptides and neurotransmitters (Joels and Baram, 2009). In particular, the stress 
mediators induce long-term adaptive responses, influencing learning and memory both 
positively and negatively (de Quervain et al., 2009). The most general view is that stress levels 
produce an inverted U-shaped dose effect in learning, memory and plasticity (Joels et al., 2006). 
Indeed, as described above, short periods of stress can potentiate memory formation, whereas 
more severe or prolonged stressors can have deleterious effects upon broad aspects of cognition, 
both in human and in rodents (Joels et al., 2006;Shors, 2006;Anacker and Hen, 2017). 
Several studies investigated the relationship among acute stress, memory and glucocorticoids 
using pharmacological and genetic tools, showing how short stressors facilitate good learning 
and memory performance (Lupien et al., 2002;Joels et al., 2006;Lupien et al., 2009). Human 
studies supported the procognitive effect produced by acute challenges (Porcelli et al., 2008) 
and oral administration of hydrocortisone improved working memory performance by 
enhancing the activity in the prefrontal cortex (PFC) (Henckens et al., 2011). Correlating, 
rodents’ studies established that acute stressors mediated the improvement of memory (Yuen 
et al., 2009;Yuen et al., 2011). However, other findings showed that acute and uncontrollable 
stress impaired cognitive functions specifically modulated by the prefrontal cortex (Arnsten, 
2009;Arnsten et al., 2015), thus underlying how the duration and the severity of the stressors 
determine the outcome of the response (Hermans et al., 2014). 
Chronic stress-induced changes in learning and memory have crucial implications for 
understanding stress-related disorders, such as depression (de Quervain et al., 2009). 
Depression is associated with deficits in cognitive capacity, with difficulties in executive 
functioning, working memory and processing speed (Chakrabarty, 2016;Ahern and 
Semkovska, 2017) and some cognitive deficits, as depressive symptoms, are listed in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM5). When these dysfunctions are 
present, they can cause considerable difficulties and functional interference in individuals’ 
everyday life. Many studies found that a wide range of antidepressants was able to improve 
cognitive related-symptoms in MDD (Gallassi et al., 2006;Herrera-Guzman et al., 2010) while 
others failed (Ferguson et al., 2003;Bastos et al., 2013). Moreover, cognitive impairments are 
residual symptoms, even when depressive disorders are successfully treated, that cause 
considerable distress (Gotlib and Joormann, 2010;Parlar et al., 2016) and constitute a serious 
risk for relapse (Paykel et al., 1995). 
The clinical relevance of the effect of stress on learning induced several studies targeting the 
neuroendocrine mechanisms, that underlie the impact of stress on memory (Schwabe, 2017), 
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with particular respect to the hippocampus, the key structure for memory (Scoville and Milner, 
1957) and to others limbic areas, such as the prefrontal cortex (Lupien et al., 1999). Numerous 
works indeed reported that exposure to elevated levels of corticosteroids impaired memory 
tasks dependent on the hippocampus (McEwen and Sapolsky, 1995;Kim and Diamond, 2002) 
and the direct role of cortisol in cognitive dysfunction was based on findings in patients with 
Cushing’s syndrome, characterized by chronic hypercorticosterolemia (Starkman et al., 1992). 
Similar, rodent’s studies showed deficits in hippocampal dependent spatial learning task due to 
both stress and corticosterone injections (de Quervain et al., 1998). 
Moreover, to provide potential advantages in this field, several studies used animal models 
exhibiting deficits in one or more of the relevant domains of cognition, to investigate the 
mechanisms underlying impaired cognitive processes observed in MDD and their dependence 
on mood pathology (fig. 5) (Darcet et al., 2016). 
 
 
Fig. 5: Behavioural paradigms in rodents used to assess cognitive functions in anxiety/depression 
models [Adapted from (Darcet et al., 2016)]. 
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1.4 Stress and Major depression 
Depressive disorders are among the most widespread forms of psychiatric pathology. 
According to the World Health Organization, about 350 million people are affected by a 
depressive disorder (Flint and Kendler, 2014) and by 2020, major depression will be the second-
leading cause of disability throughout the world after ischemic heart disease (Murray and 
Lopez, 1996). MDD is a disorder not limited to adult and elderly population, with a high 
percentage of patients that experience their first episodes of MDD during childhood and 
adolescence. In particular, in the early onset of the pathology, individuals typically continue to 
suffer during adulthood as well. For most people, MDD is a life-long episodic disorder with 
multiple recurrences with approximately 20%–25% of patients experiencing a chronic, 
unremitting course (Mueller and Leon, 1996). Functional recovery is critical for patients to 
remain in remission of MDD and return to productive and fulfilling daily lives (Zimmerman et 
al., 2006). Moreover, it has been estimated that one third of patients do not achieve remission 
after well-delivered treatments (Thase, 2010;Greden, 2013). Therefore, recovery of stress-
induced changes in neural architecture after stress is not a reversal but a form of neuroplastic 
adaptation that is impaired in mood disorders (Russo et al., 2012). 
Since the 1960s, depression has been diagnosed as “major depression” based on symptomatic 
criteria set forth in the Diagnostic and Statistical Manual. In particular, the diagnosis is made 
when a certain number of symptoms (irritability, low-self-esteem, feeling of hopelessness, 
worthlessness and guilt, decreased ability to concentrate and think, decreased or increased 
appetite, weight loss or weight gain, insomnia or hypersomnia, low fatigue or increased 
agitation, decreased interest in pleasurable stimuli, recurrent thought of death and suicide) are 
reported for longer than a 2 weeks period of time, and when the symptoms disrupt normal, 
social and occupational functioning. In addition, cognitive impairment is a common symptom 
of MDD, that often persists even after remission and during recurrent episodes. 
Despite the high prevalence of the disease, depressive disorder is complex and heterogeneous, 
with an etiology still unknown, based upon genetic predisposition and environmental factors 
that contribute to the development of the pathology. Indeed, even if there is good evidence that 
episodes of depression often occur in the context of stressful events, stress per se is not 
sufficient to cause depression. Most people do not become depressed after serious stressful 
experiences, whereas many develop the pathology. Stressful life events are known to precipitate 
depressive illness in individuals with certain genetic predispositions (Fava and Kendler, 
2000;Caspi et al., 2003) and severe stressful life events seem to be more deleterious for subjects 
who have a family history of mood disorders. A wide range of environmental events has been 
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associated with the onset of depression (Kessler, 1997) and a range of difficulties early in life 
increase the risk of developing the pathology at adulthood (Fava and Kendler, 2000). 
Among the environmental factors that can produce long-lasting modification in protein 
availability and function, epigenetic modifications could explain part of the pathophysiology of 
depression and of the antidepressant action (Krishnan and Nestler, 2010). Indeed, through 
epigenetic changes, environmental experiences can modify gene function in the absence of 
DNA sequence’s alterations. Epigenetics has been shown to explain several aspects of 
depression, including high discordance rates between monozygotic twins, individual 
differences among inbred rodents, the chronic relapsing nature of the illness and the strikingly 
greater prevalence of depression in women (Evans et al., 2005). 
Family and twin studies have provided strong evidence for the contribution of genetic factors 
to the risk of depression, with a heritability rate for depression of 37% and data from family 
studies show a two- to threefold increase in the risk of the illness in the first-degree offspring 
of patients with depression (Sullivan et al., 2000). Women have been shown to be at greater 
risk for depressive disorders than men, and the ratio of prevalence rate in women to men has 
been in the range of 1.5 to 2.5. Different studies have searched for candidate genes involved in 
the progression of depression since 1978, when the first work on this topic was published 
(Beckman et al., 1978) and more than 100 candidate genes have been analyzed to identify their 
possible association with the risk of depression (Shadrina et al., 2018). However, all this study 
failed to clearly detect the genetic association and underlying mechanism, further supporting 
that the predisposition to MDD is determined by the coordination of genes action and 
environmental factors. Altogether, stressors and the genetic predisposition of the individuals 
create a complex set up that has a relevant impact on the etiology of depression.  
Until today, several hypotheses regarding the pathogenesis of depression have been done. 
Historically, the first theory was the monoamine hypothesis, proposed by Schildkraut in the 
1960s: insufficiency of monoamine neuromediators (serotonin, norepinephrine and dopamine) 
in defined structures of the central nervous system (CNS) may lead to the development of 
depression. According to this theory, the synthesis, vesicular transport and receptors of 
monoamine mediators play an important role in the pathology and the first genetic studies 
focused on identifying and analyzing polymorphisms in genes associated with serotonin, 
norepinephrine and dopamine, as well reviewed by Shadrina and colleagues (Shadrina et al., 
2018). 
The stress-induced theory of depression is based on the statement that hyperactivity of the HPA 
system, as described above, may be an important mechanism linked with the etiology of the 
pathology. Indeed, depressed patients frequently show elevated cortisol and corticotropin levels 
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in plasma (Holsboer and Barden, 1996), increased size of the pituitary and suprarenal glands 
(Nameroff, 1996) or decreased function of glucocorticoid receptors (Modell et al., 1997). 
Moreover, excessive activation of the HPA axis is observed in the 50% of depressed people and 
chronic antidepressants attenuate this activation (Maric and Adzic, 2013). 
Another hypothesis proposes a role for neurotrophic factors in the etiology of depression and 
its treatment (Duman et al., 1997;Altar, 1999), primarily connected with the brain-derived 
neurotrophic factor (Bdnf). Some studies have reported an association between the Val66Met 
polymorphism in Bdnf with the depression onset (Schumacher et al., 2005;Ribeiro et al., 
2007;Frielingsdorf et al., 2010), even if the effect of this polymorphism has been observed only 
when associated with other genetic modifications or after exposure to severe stress (Kaufman 
et al., 2006;Pezawas et al., 2008). Furthermore, it has been found that depressed patients had 
lower levels of Bdnf in the serum with respect to healthy control subjects and that antidepressant 
treatment was able to normalize this Bdnf reduction (Shimizu et al., 2003). 
In the 1990s the hypothesis of the relationship among the immune system and the CNS in the 
involvement of neuropathological processes was suggested and in 1999 Maes proposed the 
inflammatory response system model of depression, that was later extended to the cytokine 
theory (Maes, 1999). Indeed, depressed patients display increased inflammatory markers in the 
peripheral blood (Dowlati et al., 2010) and studies on interferon administration showed a high 
rate of developing depressant symptoms, thus supporting the role of inflammation in depression 
pathogenesis (Loftis et al., 2004;Asnis and De La Garza, 2006). 
Moreover, it has been shown that disturbance of the circadian rhythm system may play a role 
in the pathology, with mutations of genes encoding for circadian proteins (Gallego and Virshup, 
2007;Gouin et al., 2010). 
The anatomical basis of depression involves many brain regions, that mediate the diverse 
symptoms of depression. For example, neocortex and hippocampus mediate cognitive aspects 
of depression whereas the striatum and amygdala are important in emotional memory, anxiety 
and motivation (Fava and Kendler, 2000). This is supported by human imaging and anatomic 
studies in the brain of depressed patients obtained at autopsy, that revealed abnormalities in 
several subregions including prefrontal and cingulate cortex, hippocampus, striatum, amygdala, 
thalamus, hypothalamus (Mayberg, 1997;Zhu et al., 1999;Rajkowska, 2000;Drevets, 
2001;Liotti and Mayberg, 2001). 
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1.5 Pharmacological treatments 
The treatment of depression was revolutionized about 60 years ago when serendipitously two 
classes of agents were discovered as antidepressant (Cahn, 2006): the tricyclic antidepressants 
(TCAs) and the monoamine oxidase inhibitors (MAOIs), which are first generation 
antidepressants. Laboratory studies revealed that these drugs increased synaptic concentrations 
of serotonin and norepinephrine and this action was hypothesized to underpin their 
antidepressant action. They enhance serotoninergic or noradrenergic transmission with several 
cholinergic side effects, that make them poorly tolerated and dangerous (Cleare et al., 2015). 
These medications provide a template for a newer class of antidepressants, the second-
generation medications: the Selective Serotonin Reuptake Inhibitors (SSRIs) and the Serotonin-
Norepinephrine Reuptake Inhibitors (SNRIs). These drugs target selectively the serotoninergic 
and noradrenergic transporter proteins: in particular, SSRIs and SNRIs block the neuronal 
serotonin transporter SERT, the neuronal noradrenaline transporter NET, or both, enhancing 
neurotransmission, presumably by slowing clearance of the transmitter and prolonging its well 
time in the synapse. 
These drugs are the most commonly used medications, which have less toxicity and improved 
safety compared to first-generation drugs (Millan, 2006;Rush et al., 2006). More recently have 
been developed drugs that not only block serotonin reuptake but also have additional effects on 
a variety of serotonin (5-HT) receptor subtypes. For example, vilazodone has partial agonist 
activity at the 5-HT1A receptor, whereas vortioxetine binds to several other 5-HT receptor 
subtypes (5HT1A, 5HT1B, 5HT1D, 5HT3, and 5-HT7). Additionally, some antidepressant agents 
do not act through the blockade of norepinephrine and serotonin reuptake. The most widely 
used is mirtazapine, which blocks α2-adrenoceptors on norepinephrine cell bodies and 
terminals, thereby facilitating norepinephrine release, with the antagonism of the 5-HT2A and 5-
HT2C receptors, that could also increase norepinephrine and dopamine release in cortical regions 
(Cleare et al., 2015).  A similar antagonist action at 5-HT2C receptors has been suggested to 
contribute to the antidepressant action of the melatonin agonist agomelatine. 
Long-term effects of antidepressant drugs suggest regulatory mechanisms that might contribute 
to the effectiveness of therapy (Shelton, 2000). However, all of these medications must be given 
for at least several weeks for their antidepressant actions to become manifest, which means that 
enhanced serotoninergic or noradrenergic neurotransmission per se is not liable for the clinical 
actions of these drugs. Despite several decades of research, and many interesting and promising 
leads, the changes that the drugs induce in the brain, at the bases of their therapeutic actions, 
remain unclear. An important progress has been done looking for drug-induced plasticity 
(Nestler et al., 2002) with the assumption that neurobiological adaptive changes, that correlate 
  19 
 
in time with the onset of the therapeutic response, could represent a more direct antidepressant 
target than the initial action of antidepressants to block serotonin and norepinephrine reuptake. 
Indeed, research has progressed beyond monoamine neurotransmitter receptors to focus on 
intracellular signaling cascades, gene expression, and protein translation as central for 
antidepressant drug action and evidence suggests that synaptic plasticity mechanisms are 
affected by chronic stress, and that antidepressant treatments reverse these effects (Harmer et 
al., 2017). These findings have defined new potential targets for antidepressant drug discovery, 
but real challenges remain in translating these to the clinic. 
Moreover, second and third-generation antipsychotic appear relevant in the treatment of mood 
disorders, in particular in the depressive phase of bipolar disorder, of resistant depression and 
of some anxiety disorders (Jarema, 2007;Javelot, 2016). 
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1.6 Animal models of depression 
Animal models of depression have been generated by employing several methods, including 
selective breeding, genetic engineering, brain lesions, and environmental manipulations.  
In the absence of known highly penetrant genetic causes of depression, much work in animal 
modeling has relied on the observation that stress and emotional losses are potent risk factors. 
In general, for the scientific community there are three main criteria for judging whether a 
particular disease model is “good enough” to investigate a pathology: the construct, the face 
and the predictive validity. Construct validity refers to the disease relevance of the methods by 
which a model is constructed: the researchers should recreate in an animal the etiologic 
processes that cause a disease in humans and thus replicate the neural and behavioral features 
of the illness (Chadman et al., 2009); face validity indicates that a model recapitulates important 
anatomical, biochemical, neuropathological, or behavioral features of a human disease whereas 
predictive (or pharmacological) validity signifies that a model responds to treatments in a way 
that predicts the effects of those treatments in humans. 
Among the several animal models of depression employed for their aetiological validity, the 
main paradigms used to investigate the effect of the environmental factor stress at adulthood 
are the chronic mild stress (CMS) or “chronic unpredictable” (CUS) stress, the “chronic social 
defeat stress, the “social isolation” and the “chronic restraint stress” (CRS). 
The “chronic mild” or “chronic unpredictable” stress consists of subjecting rodents to repeated 
physical stressors for weeks or longer periods (Willner, 2005). The protocols allow a 
combination of a large variety of stressors, that are applied to the animals over a certain period 
of time, with several number/length of intervals (fig. 6, adapted from (Yin et al., 2016). The 
model meets the three criteria: at the end of the stress protocol, animals show signs of 
anhedonia, (face validity), which can be reversed by chronic, but not acute, administration of 
antidepressant medications (predictive validity) (Nestler and Hyman, 2010). Moreover, 7 weeks 
of CMS protocol was able to induce not only anhedonia but also cognitive deficit in adult male 
rats (Calabrese et al., 2017), that were normalized by the prolonged treatment with the 
antipsychotic lurasidone (Calabrese et al., 2016) (Calabrese et al., manuscript in preparation - 
chapter 4.2). These behavioral alterations have been connected with molecular abnormalities of 
neuroplastic mechanisms (Luoni et al., 2015), inflammatory response (Rossetti et al., 2016), 
circadian rhythms (Calabrese et al., 2016) and local protein synthesis at synaptic level 
(Calabrese et al., 2017). 
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Fig. 6: Different protocols of CMS [Adapted from (Yin et al., 2016)]. 
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In the “chronic social defeat stress”, rodents are exposed to repeated bouts of social 
subordination, that lead to the development of depression-like symptoms, including anhedonia 
and social withdrawal, which can be reversed by chronic (not acute) antidepressants (Krishnan 
et al., 2007). This model also induces a metabolic syndrome in mice (Chuang et al., 2010), 
consistent with homeostatic abnormalities observed in depression. Thus, the social defeat 
paradigm exhibits feature of construct, face, and predictive validity (Hollis and Kabbaj, 2014). 
Moreover`, there is recent evidence that prolonged exposure of adult rodents to “social 
isolation” induces anhedonia, that can be treated effectively with chronic antidepressants 
(Wallace et al.). In this paradigm rodents are isolated, with differences in the duration and in 
the age at isolation, on the bases of the protocol employed. Finally, in the “chronic restraint 
stress” rodents are restrained for at minimum 2 hours per day for 14 to 21 days, protocol that 
results in depressive behavior in rats. This model, based on continuous and predictable stress, 
reproduces the repetition of stress that people experience. 
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Aim 
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Every day we are exposed to different types of stress that lead to specific biological effects on 
the bases of their type and duration. The responses to behavioral and physiological stressors are 
critical for survival under adverse conditions. Dhabhar and McEwen in 1997 gave an integrated 
definition of stress, which may recapitulate the large amount of information available in the 
literature: “stress is a constellation of events, consisting of a stimulus (stressor), that precipitates 
a reaction in the brain (stress perception), that activates physiological fight or flight systems in 
the body (stress response) (Dhabhar et al., 1997)”. This response can be either normal and 
adaptive, or abnormal and maladaptive (Selye, 1946). In particular, while exposure to acute 
stressors induce adaptive reactions that help the organism to cope with the challenges and to 
adapt efficiently to experiences in daily life, extreme stress conditions both in terms of duration 
of exposure and intensity of the stressor may lead to a maladaptive outcome, such as the 
development of psychiatric disorders. 
Indeed, stress is the major environmental factor for the etiology of depression (Chrousos and 
Gold, 1992), and it does it so by inducing stable changes in gene expression, neural circuit 
function, and behavior, which may be maintained by epigenetic modification. Actually, the 
interaction with the genetic background seems to be fundamental for the development of the 
disease (Ohadi et al., 2012), probably explaining the differences response to adverse events 
observed in humans, with some person displaying susceptibility and others resistance to the 
maladaptive effects of stress. Indeed, by activating adaptive mechanisms, the brain has the 
ability to react with the effect due to stressful changing experiences and the capability to cope 
with negative events exposure, allowing a continuous remodeling throughout the entire life 
(McEwen et al., 2015). This concept is known as resilience, a process that is at the basis of the 
differences in the individual susceptibility to stress. 
Furthermore, the consequences of chronic stress exposure during adult life may have long-
lasting effects or may be recovered, by the activation of dynamic processes to achieve a 
successful rescue (McDowell et al., 2015). Nevertheless, a high percentage of depressed 
patients experience relapse after a period of recovery, suggesting that not all the systems 
impaired by stressful environmental factors are restored, thus representing scars of 
vulnerability, that in turn can promote the relapse to the pathology.  
On these bases, by using a well-established animal model of depression, the main aim of this 
thesis was to characterize the molecular alterations associated with the development of a 
pathological phenotype as a consequence of repeated stress exposure as well as to investigate 
the ability of a pharmacological intervention to counteract or modulate the negative 
consequences of stress. In particular, we treated rats with the novel antipsychotic lurasidone, 
approved from the FDA in 2013 for the treatment of mood disorders. In addition, since stress 
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may also lead to adaptive responses in the brain, based on the timing and on the intensity of the 
exposure, we evaluated the possible beneficial effects of an acute stress condition. 
In particular, with these purposes, the main objectives of this study were to: 
- characterize the behavioral phenotype of chronically stressed rats, focusing on the anhedonic 
phenotype and on the cognitive abilities, to assess the different susceptibility to stress;  
- dissect the molecular mechanisms associated with the development of the susceptible and 
resilient phenotypes; 
- investigate the epigenetic mechanisms that may contribute to stress-induced abnormalities; 
- identify the molecular alterations that may persist after a recovery period following stress 
exposure; 
- investigate the ability of the pharmacological treatment with the antipsychotic drug lurasidone 
to correct the behavioral defects induced by stress exposure; 
- determine the ability of lurasidone to influence the long-lasting molecular consequences of 
chronic stress as well as to modulate the response to a new stress later in life; 
- characterize the behavioral consequences induced by the exposure to an acute stressor 
- evaluate the molecular mechanisms responsible for the adaptive response mediated by the 
effect of an acute challenge on the cognitive performance.  
The molecular mechanism on which we focus on, were analyzed in brain areas of specific 
interest for stress and related disorders, namely prefrontal cortex and dorsal hippocampus 
(dHip), because stressful experiences have functionally-relevant effects on these brain area 
(Kim and Yoon, 1998), that mediate neuroendocrine, autonomic function as well as cognitive 
and emotional regulation (Kim and Diamond, 2002;McEwen and Gianaros, 2011). 
To address these aims, we employed the chronic mild stress paradigm that recapitulates in 
rodents the features of the illness. Indeed, the CMS paradigm meets the criteria of construct, 
face and predictive validity, that classify this as a useful animal model to investigate the 
neurobiological and molecular mechanisms that may be critical in the pathogenesis of major 
depression.  
Our results provided information regarding systems and pathways through which stress can 
impact brain physiology and contribute to the development of the illness, thus providing new 
knowledge on the molecular basis of major depression, which may be useful not only for basic 
science but also for prevention as well as for the treatment of stress-related disorders.  
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Material and methods 
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1.7 Animals 
Experiments 1 and 2: Male Wistar rats (Charles River, Germany) were brought into the 
laboratory one month before the start of the experiment. The animals were housed with food 
and water freely available and were maintained on a 12-h light/dark cycle and in a constant 
temperature (22 ± 2oC) and humidity (50 ± 5%) conditions. All procedures used in this study 
have conformed to the rules and principles of the 86/609/EEC Directive and have been 
approved by the Local Bioethical Committee at the Institute of Pharmacology, Polish Academy 
of Sciences, Krakow, Poland.  
Experiments 3 and 4: Male Sprague-Dawley rats (Charles River, Italy) were brought into the 
laboratory two weeks before the start of the experiment. Rats were housed with food and water 
freely available and were maintained on a 12-h light/dark cycle and in a constant temperature 
(22 ± 2oC) and humidity (50 ± 5%) conditions. All procedures used in this study have 
conformed to the rules and principles of the 2010/63/UE Directive, according to the 
authorizations from the Health Ministry n 151/2017-PR. 
 
1.8 Stress procedure 
Experiments 1 and 2: Chronic mild stress (CMS). After a period of adaptation to laboratory and 
housing conditions, the rats were randomly divided into two matched groups. One group (no 
stress) were housed in separate rooms and had no contact with the stressed animals while the 
other group of animals was subjected to the chronic mild stress procedure for a period of 7 
consecutive weeks. Each week of stress regime consisted of: two periods of food or water 
deprivation, two periods of 45-degree cage tilt, two periods of intermittent illumination (lights 
on and off every 2h), two periods of soiled cage (250 ml water in sawdust bedding), one period 
of paired housing, two periods of low intensity stroboscopic illumination (150 flashes/min), and 
three periods of no stress. All stressors were 10 - 14 h of duration and were applied individually 
and continuously, day and night.  
Experiment 3: Chronic restraint stress (CRS). After two weeks of adaptation to laboratory and 
housing conditions, rats were divided into two groups (no stress and CRS). CRS group rats 
were exposed to an unpredictable chronic restraint stress for 4 weeks. Rats were placed in an 
air-assessable cylinders (fig. 7) for 1 hour two times/day at random hours, to avoid habituation. 
The dimensions of the restrainer were similar to the size of the animal, which made the animal 
almost immobile in it. Rats were than left undisturbed for a period of three weeks of recovery 
(washout). Following the washout period, rats were exposed to one hour of acute restraint stress 
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(fig. 10).  
Experiment 4: Acute restraint stress. After two weeks of adaptation to laboratory and housing 
conditions, rats were exposed to one hour of acute stress, in an air-assessable cylinders (the size 
of the device was similar to the size of the animal, which made the animal almost immobile in 
the container). 
 
Fig. 7: Schematic representation of the restrainer  
 
1.9 Pharmacological treatment 
Experiment 2: Both control and CMS groups, after two weeks of stress protocol, were each 
divided further into matched subgroups, and for subsequent five weeks they received daily 
administration of vehicles (1% (w/v) hydroxyethylcellulose, 1 ml/kg, PO) or lurasidone (3 
mg/kg, PO). The volume of all injections was 1 ml/kg. The drugs were administered at approx. 
10.00 am. 
Experiment 3: Starting from the second week of chronic restraint stress protocol, both CRS and 
control groups were each divided and for three weeks they received once daily administration 
of vehicles (1% (w/v) hydroxyethylcellulose, 1 ml/kg, PO) or lurasidone (3 mg/kg, PO). The 
volume of all injections was 1 ml/kg. The drugs were administered in the morning, depending 
on the random exposure to the restraint stress session. 
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1.10 Behavioural tests 
1.10.1 Sucrose consumption test. 
Experiments 1 and 2 
To assess the development of the anhedonia, one of the core symptoms of depression, rats were 
tested at weekly intervals throughout the whole experiments with the sucrose consumption test. 
In particular, during the period of adaptation in the housing conditions, the animals were trained 
to consume 1% sucrose solution; training consisted of nine 1h baseline tests, in which sucrose 
was presented, in the home cage, following 14h food and water deprivation. The sucrose intake 
was measured by weighing pre-weighed bottles containing the sucrose solution, at the end of 
the test.  
 
1.10.2 Novel object recognition test 
Experiments 1, 2 and 4. 
The animals were tested in non-transparent open fields (100 cm in diameter, 35 cm high, with 
the floor divided into painted 16-cm squares). After 10-min adaptation sessions on two 
successive days, the animals were allowed to explore two identical objects (white cylinders, 7 
cm in diameter, 11 cm high) for the time required to complete 15 s of exploration of both objects 
(trial session). In the retention trial conducted one hour later (testing session), one of the objects 
presented previously was replaced by a novel object (black prism, 5 cm wide, 14 cm high). Rats 
were returned to the open field and the duration of exploration of each object (ie. sitting in close 
proximity to the objects, sniffing or touching them) was measured during a 5 min test. A NOR 
index was calculated according to the following formula: time of novel object exploration 
divided by time of novel plus familiar object exploration, multiplied by 100.  
In the experiment 1, at the end of the 7 weeks of chronic mild stress and in the experiment 2, 
after five weeks of lurasidone administration, all control and stressed animals were randomly 
divided into two cohorts. One cohort (NOR) was tested in a Novel Object Recognition test and 
the second cohort (Naive) was left intact (fig. 8 and 9, respectively).  
In the experiment 4, non-stressed and acutely stressed rats were divided into subgroups and 
stressed animals were tested in the NOR 1 hour, 4 hours and 24 hours after the acute challenge 
(fig. 11). 
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1.10.3 Locomotor activity test 
In the experiment 1, the locomotor activity was monitored in a non-transparent open fields 
measuring 100 cm in diameter, 35 cm high and with the floor divided into painted 16-cm 
squares. The number of line crossings was recorded as a measure of locomotor activity.  
 
1.11 Experimental paradigms 
The experimental paradigms we designed for our studies are the following: 
Experiment 1: Adult male rats were subjected to 7 weeks of chronic mild stress and exposed to 
the novel object recognition test (NOR) or to the empty arena (Sham) 
 
Fig. 8: Schematic representation of the experimental groups of the first paradigm 
 
Experiment 2: Adult male rats were exposed to 7 weeks of chronic mild stressed, treated for 5 
weeks with lurasidone (3mg/kg/day) and tested with the novel object recognition test 24 hours 
after last drug injection 
 
Fig. 9: Schematic representation of the experimental groups of the second paradigm 
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Experiment 3: Adult male rats were subjected to 4 weeks of chronic restraint stress, treated 
with lurasidone (3mg/kg/day) for 3 weeks, tested to the novel object recognition and exposed 
to an acute challenge after three weeks of recover from stress 
 
Fig. 10: Schematic representation of the experimental groups of the third paradigm. 
 
Experiment 4: Adult male rats were exposed to 1 hour of restraint stress and tested to the novel 
object recognition test 1, 4 or 24 hours later 
 
Fig. 11: Schematic representation of the experimental groups of the fourth paradigm. 
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1.12 Molecular analyses 
The molecular analyses were conducted in the prefrontal cortex and in the dorsal hippocampus, 
dissected from the fresh brain after rat decapitation.  
In the experiment 1, rats were killed immediately after the end of the NOR test or to the sham 
exposure; in the experiment 2, rats were decapitated immediately after the end of the NOR test 
or 24 hours after the last lurasidone injection. In the experiment 3, rats were killed 1 hour after 
the acute restraint stress whereas in the experiment 4, 1, 4 or 24 hours after the acute restraint 
stress or immediately after the end of the NOR test. 
Specifically, the prefrontal cortex (defined as Cg1, Cg3 and IL subregions corresponding to the 
plates 6-10 according to the atlas of Paxinos and Watson (Paxinos and Watson, 1998) was 
dissected from 2-mm-thick slices, whereas the dorsal hippocampus (plates 25-33 according to 
the atlas of Paxinos and Watson) was dissected from the whole brain. The brain specimens were 
then rapidly frozen in dry ice and stored at -80° C for the molecular analyses.  
 
1.12.1 RNA preparation and real time RT-PCR 
For gene expression analyses, total RNA was isolated from the different brain regions by single 
step guanidinium isothiocyanate/phenol extraction using PureZol RNA isolation reagent (Bio-
Rad Laboratories S.r.l.; Segrate, Italy) according to the manufacturer’s instructions and 
quantified by spectrophotometric analysis. The samples were then processed for real-time 
polymerase chain reaction (PCR) to assess mRNA levels of several genes (table 1a/b). 
Briefly, an aliquot of each sample was treated with DNase to avoid DNA contamination and 
subsequently analyzed by TaqMan qRT–PCR instrument (CFX384 real-time system, Bio-Rad 
Laboratories S.r.l.) using the iScript one-step RT–PCR kit for probes (Bio-Rad Laboratories 
S.r.l.). Samples were run in 384-well format in triplicates as multiplexed reactions with a 
normalizing internal control (36B4). Thermal cycling was initiated with incubation at 50°C for 
10 min (RNA retrotranscription), and then at 95 oC for 5 min (TaqMan polymerase activation). 
After this initial step, 39 cycles of PCR were performed. Each PCR cycle consisted of heating 
the samples at 95 °C for 10 s to enable the melting process and then for 30 s at 60 °C for the 
annealing and extension reactions. A comparative cycle threshold (Ct) method was used to 
calculate the relative target gene expression. The primers (f: forward; r: reverse) and probe (p) 
sequences used were purchased from Eurofins MWG-Operon and are reported in Table 1  
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a) Gene Forward primer Reverse primer Probe 
Arc GGTGGGTGGCTCTGAAGAAT ACTCCACCCAGTTCTTCACC GATCCAGAACCACATGAATGGG 
Npas4 TCATTGACCCTGCTGACCAT AAGCACCAGTTTGTTGCCTG TGATCGCCTTTTCCGTTGTC 
Sgk1 GACTACATTAATGGCGGAGAGC AGGGAGTGCAGATAACCCAAG TGCTCGCTTCTACGCAGC 
Dusp-1 TGTGCCTGACAGTGCAGAAT ATCTTTCCGGGAAGCATGGT ATCCTGTCCTTCCTGTACCT 
Fkbp5 GAACCCAATGCTGAGCTTATG ATGTACTTGCCTCCCTTGAAG TGTCCATCTCCCAGGATTCTTTGGC 
P11 AGAGTGCTCATGGAAAGGGA AGCTCTGGAAGCCCACTTTT ATAATGAAAGACCTGGACCAGTGC 
Nr3c1 GAAAAGCCATCGTCAAAAGGG TGGAAGCAGTAGGTAAGGAGA AGCTTTGTCAGTTGGTAAAACCGTTGC 
36B4 TTCCCACTGGCTGAAAAGGT CGCAGCCGCAAATGC AAGGCCTTCCTGGCCGATCCATC 
b) Gene Accession number Assay ID  
Gadd45b BC085337.1 Rn01452530_gI  
Nr4a1 BC097313.1 Rn01533237_m1  
Cox-1 NC_001665.COX1.0 Rn03296721_s1  
Cox-3 NC_001665.COX3.0 Rn03296820_s1  
Table 1: a) Sequences of forward and reverse primers and probes used in Real-time PCR analyses and 
purchased from Eurofins MWG-Operon. b) Probes purchased from Life Technologies, which did not 
disclose the sequences. 
 
1.12.2 Protein extraction and western blot analyses 
Western blot analysis was used to investigate GluN1 (phospho Ser896 and total), GluN2B 
(phospho Ser1303 and total), mTOR (phospho Ser2448 and total), eEF2, (phospho Thr56 and 
total) OLIGOPHRENIN-1 (OPH-1), BMAL1, ARC, GR and SYNAPSIN I (phospho Ser603 
and total) in the subcellular fractions. Tissues were manually homogenized using a glass-glass 
potter in a pH 7.4 cold buffer containing 0.32 M sucrose, 0.1 mM EGTA, 1 mM HEPES solution 
in the presence of a complete set of proteases (Roche) and phosphatases (Sigma-Aldrich) 
inhibitors. The total homogenate was centrifuged at 2,500 rpm for 10 min at 4°C to obtain a 
pellet enriched in nuclear components, which was suspended in a buffer (20 mM HEPES, 0.1 
mM dithiothreitol (DTT), 0.1 mM EGTA) with protease and phosphatase inhibitors. The 
supernatant obtained was further centrifuged at 10,000 g for 15 min at 4°C to obtain the pellet 
corresponding to the membrane fraction (including both synaptic and mitochondrial contents) 
which was re-suspended in the same buffer prepared for the nuclear fraction. Total proteins 
were measured according to the Bradford Protein Assay procedure (Bio-Rad Laboratories), 
using bovine serum albumin as a calibration standard. Equal amounts of protein were run under 
reducing conditions on 10% SDS-polyacrylamide gels and then electrophoretically transferred 
onto nitrocellulose membranes (Bio-Rad Laboratories). The blots for GR were blocked with 
BSA in TBS+0,2%sodium azide, while the ones for the other proteins with 10% non-fat dry 
milk and then were incubated with the primary antibodies summarized in Table 2. Membranes 
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were then incubated for 1 hour at room temperature with the opportune secondary antibody (see 
Table 2). 
Immunocomplexes were visualized by chemiluminescence using the Western Lightning Plus 
ECL (Euroclone) and the Chemidoc MP imaging system (Bio-Rad Laboratories). Results were 
standardized using b-actin as the control protein, which was detected by evaluating the band 
density at 43 kDa.  
 
Protein Primary antibody Secondary antibody 
phospho GluN1 Ser 896 1:1000 (Santa Cruz),, 4°C, O/N anti-rabbit, 1:5000, RT, 1h 
GluN1 1:1000 (Invitrogen), 4°C, O/N anti-mouse, 1:3000, RT, 1h 
phospho GluN2B Ser1303 1:1000 (Up State), 4°C, O/N anti-rabbit, 1:2000, RT, 1h 
GluN2B 1:1000 (Santa Cruz), 4°C, O/N anti-goat, 1:2000, RT, 1h 
phospho mTOR Ser2448 1:1000 (Cell Signaling), 4°C, O/N anti-rabbit, 1:1000, RT, 1h 
mTOR 1:1000 (Cell Signaling), 4°C, O/N anti-rabbit, 1:1000, RT, 1h 
phospho eEF2 Thr56 1:1000 (Cell Signaling), 4°C, O/N anti-rabbit 1:1000, RT, 1h 
eEF2 1:1000 (Cell Signaling), 4°C, O/N anti-rabbit 1:1000, RT, 1h 
OPHN-1 1:100 (Santa Cruz), 4°C, O/N anti-mouse 1:1000, RT, 1h 
BMAL1 1:5000 (Cell Signaling), 4°C, O/N anti-rabbit 1:2500, RT, 1h 
ARC 1:500 (BD), 4°C, O/N anti-mouse, 1:1000, RT, 1h 
GR 1:500 (ThermoFisher), 4° O/N 1:2000 Anti-rabbit (Cell signaling), 1h RT 
phospho SYNAPSIN I Ser603 1:2000 (Upstate), 4° O/N 1:5000 Anti-rabbit (Cell signaling),1h RT 
SYNAPSIN Ia/b 1:5000 (Abcam), 4° O/N 1:4000 Anti-goat (Jacksonreasearch), 1h RT 
b-Actin 1:10000 (Sigma), 1h RT 1:10000 Anti-mouse (Sigma),1h RT 
Table 2: conditions of the antibodies used in western blot analysis (O/N: over/night; RT: room 
temperature) 
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1.12.3 DNA extraction, bisulfite treatment and DNA methylation analyses 
DNA samples of prefrontal cortex were extracted using the AllPrep DNA/RNA/miRNA 
Universal Kit (Qiagen) and stored at −80 °C. An aliquot of 0.5 μg of DNA was treated with 
sodium-bisulfite with the EZ-96 DNA Methylation-Gold kit (Zymo Research). Both procedures 
were executed according to the manufacturer's instructions. DNA methylation analysis was 
carried out using bisulfite-PCR-pyrosequencing. The bisulfite-treated genomic DNA samples 
were amplified with PCR for the regions of interest. CpG sites within the promoter regions of 
Nr3c1 and in the glucocorticoid responsive element of Gadd45b and Sgk1 were investigated. 
Detailed information concerning primer sequences and genomic regions is listed in table 3. 
Pyrosequencing of the PCR products was carried out using the PyroMark MD Pyrosequencing 
System (Qiagen) (Bollati et al., 2007). The percentage of 5-methylcytosine (%5mC) was 
presented as the percentage of cytosine that was methylated divided by the sum of methylated 
and unmethylated cytosines. 
 
Gene 
Chromosome position 
(RGSC_6.0) 
Region CpG 
loci 
 Primers (F), reverse (R) and 
sequencing (S) 
  
Nr3c1 Chr18:31,728,373-32,704,022 promotor 4 
 F: biotin-
GGGATTTTTAAGAGGTTAGGTAGAG 
R: ATAACTTTTACTCCCCCACAAATAC 
S: ACCATAACTCCACCTCATACCC 
 
  
Gadd45b Chr7:11,646,283-11,648,338 exon 5 
 F: Biotin-
GTTAAGATAGGAAGGAGGGGATTT  
R: AAAACAAGAAAACTTAACCAATTT  
S: ACAATTCACTATCCAAC 
 
  
Sgk1 Chr1:24,185,451-24,302,309 promotor 2 
 F: GTATTAGGGTAAGGGTATTGATT  
R: Biotin-
TCATTTCACTTTTTTTTCCAACTA 
S: TTGTAAGGTTTAAAATTTAT 
  
Table 3. Pyrosequencing assay information (F: forward; R: reverse; S: sequencing). 
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1.13 Statistical analyses  
1.13.1 Behavioral analyses 
In the experiments 1 and 4, the results of the behavioral test (sucrose consumption test and/or 
novel object recognition test) were analyzed with the one-way analysis of variance (ANOVA) 
followed by Fisher LSD Post Hoc Test (PLSD), whereas in the experiments 2 was used the 
two-way ANOVA, with stress and pharmacological treatment as independent factors, followed 
by PLSD. Moreover, in experiments 1 and 2, the analyses of sucrose consumption during the 
whole stress paradigms were performed with two-way ANOVA with repeated measures. 
Significance for all tests was assumed for p<0.05. Data are presented as means ± standard error 
(SEM). For graphic clarity, results are presented as means percent of no stress rats. 
 
1.13.2 Molecular analyses 
In the experiment 1, the effects of stress (no stress/CMS) and/or the behavioral manipulation 
(exposure to the empty arena, Sham, or to the NOR test) as independent factors, were analyzed 
with the two-way ANOVA, followed, when appropriate, by Fisher’s protected Least Significant 
Difference test. In addition, to evaluate the association between the development of cognitive 
deficits and the alteration of protein expression, Pearson correlation coefficients (r) were 
evaluated between NOR index of single animals and the corresponding protein levels. 
In the experiment 2, the effect of chronic mild tress (no stress/CMS) and of the behavioral 
manipulations (naïve/NOR), or of the pharmacological treatment (VEH/LUR), as independent 
factors, were analyzed with the two-way ANOVA, followed, when appropriate, by PLSD. 
In the experiment 3, the effect of chronic restraint stress (no stress/CRS), of the treatment 
(VEH/LUR) as independent factors, were analyzed with the two-way ANOVA, followed, when 
appropriate, by PLSD. Moreover, the three-way ANOVA with PLSD was used to investigate 
the effect of chronic restraint stress (no stress/CRS), of the pharmacological treatment 
(VEH/LUR) and of the acute restraint challenge (no stress/restraint), as independent factors. 
In the experiment 4, the effect of the acute stress was analyzed with the one-way ANOVA with 
PLSD, whereas the two-way ANOVA with PLSD was used to evaluate the effect of both the 
acute challenge (no stress/ restraint) and the NOR test (naïve/NOR), as independent factors. 
Significance for all tests was assumed for p<0.05. Data are presented as means ± standard error 
(SEM). For graphic clarity, results are presented as means percent of no stress rats.  
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Results and discussion 
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1.14 Chronic mild stress-induced alterations of local protein synthesis: a role for 
cognitive impairment 
Calabrese F, Brivio P, Gruca P, Lason-Tyburkiewicz M, Papp M, Riva MA 
ACS Chemical Neuroscience 2017 Apr, 19;8(4):817-825. doi:10.1021/acschemneuro.6b00392. 
Epub 2017 Feb 3. 
 
Depression, a major cause of disability worldwide, is characterized by a complex and 
heterogeneous symptomatology. With this respect, cognitive deterioration represents a major 
problem that has a strong impact on patient’s function. Indeed, cognitive dysfunctions are 
characteristic of MDD and are among the persistent symptoms, that can weaken the general 
performance and cause distress, during both the active phase of the disease and remission. In 
this context it is not fully clear which are the mechanism underlying the link between cognitive 
deficits and MDD. Since altered synaptic plasticity has been related with depression and 
psychiatric disorders, here we focus on de-novo protein synthesis at synaptic levels, to evaluate 
its possible involvement in the memory maintenance under physiological conditions as well as 
its potential association with the pathogenesis of mood disorders (Hoeffer and Klann, 2010). 
In this study, we employed the chronic mild stress paradigm to induce a depressive like 
behavior, including cognitive deficits, in adult male rats. At molecular levels, we focus on the 
neuronal activity and we dissected, at synaptic level, the protein synthesis pathway driven by 
mammalian target of rapamycin (mTOR) activation, specifically in the dorsal sub region of the 
hippocampus known to be involved in memory and learning processes. One of the main 
mechanisms in protein synthesis-dependent memory is the signaling cascades associated with 
de novo protein synthesis linked with mammalian target of rapamycin complex 1 and the 
eukaryotic initiation factor 2 (eIF2) (Graber et al., 2013;Trinh and Klann, 2013). Moreover, 
mTOR activation through NMDA receptors is also involved in peptide elongation, with the 
involvement of the eukaryotic elongation factor 2 (eEF2) and the translation of specific mRNA 
(fig. 16B). 
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1.14.1 Results 
1.14.1.1 Behavioral characterization of chronically stressed rats  
As shown in figure 12A, one week of chronic mild stress reduced the consumption of 1% 
sucrose solution, specifically in a sub population of stressed rats, an effect that persisted for the 
subsequent 6 weeks of CMS. We defined this vulnerable group as “stress reactive”, whereas 
the rats that did not develop anhedonia were named “stress non-reactive”, since they had, for 
the whole 7 weeks CMS period, a sucrose intake similar to non-stressed rats. 
At the end of the stress protocol, we found that 7 weeks of stress exposure exerted a significant 
effect on sucrose consumption (F2,40=22.40, p<0.001) (fig. 12B). Indeed, among stressed rats, 
about the 80% showed a significant reduction of sucrose intake (-7.6g; p<0.001 vs no stress), 
while the remaining 20% was resilient since they consumed the same amount of sucrose as the 
control animals (+0,6g; p>0.05 vs no stress)  
Conversely, when we tested the animals in the novel object recognition, we found that CMS 
exposure, independently from the anhedonic phenotype produced a significant impairment of 
the cognitive performance (F2,16=9.99, p<0.01) (fig. 12C). Indeed, we observed a significant 
decrease of the NOR index in stress reactive (-37%; p<0.001 vs no stress) as well as in stress 
non-reactive (-30%; p<0.01 vs no stress) animals. Notably, stressed rats did not show any defect 
in the locomotor activity (fig. 12D) (F2,16=2.785, p>0.05). 
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Fig. 12: Behavioural characterization of animals exposed to CMS. Panel A shows the sucrose intake 
performed every week while panel B reports the results of the test after 7 weeks of CMS. The data are 
expressed as grams of consumed sucrose. The results of the Novel object recognition test and of the 
locomotor activity test are summarized in the panel C and D respectively. **p<0.01, ***p<0.001 vs no 
stress (one-way ANOVA with repeated measures panel A; one-way ANOVA with PLSD panel B-C-D). 
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1.14.1.2 Modulation of Arc and Npas4 mRNA levels after the Novel object recognition test in 
the dorsal hippocampus of control and stressed rats  
The immediate early genes (IEGs) are markers of neuronal activity. They encode transcription 
factors that influence neuronal physiology, that in turn regulate late response genes. Even if 
their role in many biological processes is still unknown, they are related to learning and memory 
(Gallo et al., 2018), as they are involved in long term memory formation and maintenance in 
specific neuronal populations (Rosen et al., 1998;Guzowski et al., 1999;Ramirez-Amaya et al., 
2005;Minatohara et al., 2015). 
Here we focus on Arc and Npas4 gene expression and the molecular analyses were performed 
in sham animals (who were exposed to the empty arena) as well as in NOR-tested rats, in order 
to identify specifically the changes produced by the exposure to a novel environment from those 
linked to the learning process.  
Arc and Npas4 genes expression was significantly affected by the behavioral manipulation 
(F2,35=21.588, p<0.001; F2,36=39.655, p<0.001) independently from the stress exposure. 
Moreover, Arc and Npas4 mRNA levels were significantly increased both in Sham animals 
(Arc: no stress, +393%, p<0.001; stress reactive, +192%, p<0.05; Npas4: no stress, +206%, 
p<0.001; stress reactive: +562%, p<0.001) and in those exposed to the test (NOR) (Arc: no 
stress, +296%, p<0.001; stress reactive +252%, p<0.01; Npas4: no stress, +212%, p<0.001; 
stress reactive, +313%, p<0.001) (fig. 13A-B). 
These changes appear to be due to a non-specific neuronal activation, since we found that the 
gene expression of this two activity regulated immediate early genes was significantly increased 
after the NOR test independently from the pre-exposure to the chronic stress procedure. 
Furthermore, we observed these inductions also in rats exposed to the empty arena (sham 
groups), suggesting that the neuronal responsiveness is mainly driven by the new experience 
both in non-stressed and in stressed animals. 
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Fig.13: Analysis of Arc and Npas4 mRNA levels in the dorsal hippocampus of chronically stressed rats 
exposed to the novel object recognition test (NOR). The mRNA levels of Arc and Npas4 were measured 
in non-stressed and chronically stressed rats exposed to the empty arena (Sham) or to the test (NOR). 
The data are expressed as a percentage of no stress/Naive (set at 100%). ***p<0.001 vs no stress/Naive, 
# p<0.05, ## p<0.01, ### p<0.001 vs stress reactive/Naive (two-way ANOVA with PLSD). 
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1.14.1.3 Modulation of NMDA receptor subunits after the novel object recognition test in the 
crude synaptosomal fraction of the dorsal hippocampus of control and chronically 
stressed rats 
Among the different pathways implicated in learning and memory formation, the glutamatergic 
system plays a fundamental role. On this basis, we measured the activated as well as the total 
form of two NMDA receptor subunits: the mandatory GluN1 and the accessory GluN2B. In the 
crude synaptosomal fraction, we did not observe any effect on either the phosphorylated 
(Ser896) (fig. 14A) or the total form of the GluN1 subunit (fig. 14B). On the contrary, for 
GluN2B activation we found a significant effect of the cognitive test (F2,30=21.236, p<0.001) 
of stress (F1,30=6,769, p<0.05) and a significant stressXtest interaction (F2,30=3.503, p<0.05) 
(fig. 14C). Indeed, as confirmed by the post hoc test, phospho-GluN2B Ser1303 levels were 
significantly increased after the NOR test in no stress animals (+93% p<0.001 vs no 
stress/Naive) but not in those exposed to 7 weeks of CMS (+30% p>0.05 vs stress 
reactive/Naive). Interestingly, we did not observe this effect in animals exposed only to the 
empty arena (Sham) (no stress: -29% p>0.05 vs no stress/Naïve; stress reactive: -33%, p>0.05 
vs stress reactive/Naive), suggesting that this modulation seems to be specific for the learning 
processes. Moreover, also the total form of GluN2B (fig. 14D) was significantly affected by the 
acute manipulation (F2,34=6.052, p<0.05). Indeed, we found a significant decrease after the 
exposure to the test in both groups (no stress: -45% p<0.05 vs no stress/Naïve; stress reactive: 
-34%, p<0.05 vs stress reactive/Naive) as confirmed by the lack of a significant stress X test 
interaction (F2,34=3.102, p>0.05).  
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Fig. 14: Analysis of GluN1 and GluN2B, in the crude synaptosomal fraction of the dorsal hippocampus 
of chronically stressed rats exposed to the novel object recognition test (NOR). Phosphorylated and total 
levels of GluN1 and GluN2B were measured in non-stressed and chronically stressed rats exposed to 
the empty arena (Sham) or to the test (NOR). Panel E: Representative Western blot analyses of GluN1 
(pSer896, tot), GluN2B (pSer1303, tot). β-ACTIN was used as internal standard. The data are expressed 
as a percentage of no stress/Naive (set at 100%). *p<0.05, ***p<0.001 vs no stress/Naive. # p<0.05 vs 
stress reactive /Naive (two-way ANOVA with PLSD). 
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1.14.1.4 Modulation of mTOR after the Novel object recognition test in the crude synaptosomal 
fraction of the dorsal hippocampus of control and stressed rats 
One of the downstream systems activated by the NMDA receptors is mTOR. Interestingly, 
phospho-mTOR Ser2448 was significantly increased after the NOR test specifically in no stress 
animals (+44% p<0.05 vs no stress/Naive) (fig. 15A), but not in stress reactive rats (+0% p<0.05 
vs stress reactive/Naive), whereas its total levels were not affected in any of the experimental 
groups (fig 15B). The exposure to the empty arena did not exert any significant effect (no stress: 
-5% p>0.05 vs no stress/Naïve; stress reactive: +9%, p>0.05 vs stress reactive /Naive), 
suggesting that the increased phosphorylation of mTOR on Ser2448, as well as the activation 
of GluN2B, may indeed be related to the cognitive performance.  
 
 
Fig. 15: Analysis of mTOR protein levels in the crude synaptosomal fraction of the dorsal hippocampus 
of chronically stressed rats exposed to the novel object recognition test (NOR). Phosphorylated and total 
levels of mTOR were measured in non-stressed and chronically stressed rats exposed to the empty arena 
(Sham) or to the test (NOR). The data are expressed as a percentage of no stress/Naive (set at 100%). 
Panel C: Representative Western blot analyses of mTOR (pSer2448, tot). β-ACTIN was used as internal 
standard. *p<0.05 vs no stress/Naive (two-way ANOVA with PLSD). 
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1.14.1.5 Analysis of eEF2 mediated translation in the crude synaptosomal fraction of the dorsal 
hippocampus of control and stressed rats  
NMDAR and mTOR activation not only controls translational initiation but is also involved in 
peptide elongation. On these bases, we decided to analyze the phosphorylated as well as the 
total form of eEF2 in our experimental paradigm.  
Interestingly, exposure to the cognitive test significantly increased peEF2/eEF2 (fig. 16A) in 
no stress (+108% p<0.05 vs no stress/Naive), but not in stress reactive rats (-25% p<0.05 vs no 
stress/Naive).  
Since it has been previously demonstrated that the presence of uORF in the gene sequence is 
fundamental for the translation of the corresponding mRNAs driven by an increase of peIF2α, 
we explored if a similar mechanism may be associated with the phosphorylation of eEF2 (fig. 
16B).  
Hence, we investigated the protein levels of genes characterized by the presence of a different 
number of uORF, namely oligophrenin-1 (OPHN-1) (2 uORFs), BMAL-1 (7 uORFs) and ARC 
(0 uORFs) (fig. 16C). We found a significant increase in the OPHN1 protein levels after the 
NOR test, an effect that was larger in no stress (+404 p=0.001 vs no stress/Naïve) as compared 
to CMS animals (+123 p<0.05 vs stress reactive/Naïve) Furthermore, the protein levels of 
BMAL-1 were significantly up-regulated following the behavioral test in no stress rats (+68% 
p<0.05 vs no stress/Naive,) but not in CMS rats (-25% p<0.05 vs no stress/Naive), as suggested 
by the significant stressXtest interaction (F1,21=8.332, p<0.05). Conversely, ARC protein 
levels were not affected in our experimental conditions suggesting that, similarly to what found 
for eIF2α, this gene-specific translational control depends on the presence of uORFs. 
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Fig. 16: Analysis of peEF2/eEF2, OPHN-1, BMAL-1 and ARC protein levels in the crude synaptosomal 
fraction of the dorsal hippocampus of chronically stressed rats exposed to the novel object recognition 
test (NOR). The data are expressed as a percentage of no stress/Naive (set at 100%). Panel B shows a 
schematic representation of the mechanism investigated. Briefly, we aim to investigate if the gene 
specific translational control by peEF2 depends on the presence of uORFs in the mRNAs sequence. 
Panel D: Representative Western blot analyses of peEF2 Thr56, eEF2, OPHN-1, BMAL1 and ARC. β-
actin was used as internal standard. * p<0.05, **p<0.01 vs no stress/Naïve; # p<0.05 vs stress 
reactive/Naive (two-way ANOVA with PLSD). 
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1.14.1.6 NOR index correlates with the protein levels of pGluN2B Ser1303, pmTOR Ser2448 
and peEF2/eEF2 
NOR index was examined for possible covariation within the protein levels of pGluN2B, 
pmTOR and peEF2/eEF2. The analyses revealed that NOR index positively correlates with the 
expression of pGluN2B (r = 0.7195, n=10, p<0.05) (fig. 17A), pmTOR (r = 0.6803, n=11, 
p<0.05) (fig. 17B) and peEF2/eEF2 (r = 0.7667, n=10, p<0.01) (fig. 17C).  
 
 
Fig. 17: Correlation analyses between pGluN2B Ser1303 (A), pmTOR Ser2448 (B), peEF2Thr56/eEF2 
(C) and NOR index in the dorsal hippocampus of non-stressed and chronically stress-reactive rats, 
exposed to NOR. Analyses by Pearson’s product-moment correlation (r).  
  
  49 
 
1.14.2 Discussion 
In this study, we showed that exposure to chronic mild stress produces cognitive deficits that 
are not related to the development of the anhedonic phenotype. Indeed, after 7 weeks of stress, 
independently from the hedonic phenotype, all the animals show cognitive deficits, as 
demonstrated by the reduced performance in the NOR test observed in stress reactive as well 
as in stress non-reactive rats (resilient to anhedonia). Moreover, our data suggest that the 
cognitive deficits developed following CMS are associated with an inability to activate the 
synthesis of new proteins specifically at the synaptic level. 
Despite the fact that cognitive impairment has a disabling effect on patients and represents a 
major problem for the management of depressed patients, most of the studies have used stress-
based models to investigate the mechanisms that contribute to anhedonia, despair, anxiety and 
fear, rather than focusing on cognitive deficits. Moreover, while currently available drugs may 
improve these symptoms of depression, cognitive deficits are not improved and may even be 
worsened (Millan et al., 2012). 
Interestingly, at molecular levels, we found that the exposure to the NOR test, but not the 
novelty, induced the activation of the NMDAR in the crude synaptosomal fraction of the control 
rats. Conversely, but similarly to what found at the behavioral level, this effect did not occur in 
the stressed animals, suggesting that the cognitive deficits observed may be due to the lack of 
glutamate receptor activation. Accordingly, mTOR phosphorylation was specifically increased 
in normal animals, but not in those exposed to the chronic stress. Actually, these changes appear 
to be due to the cognitive test and not to a non-specific neuronal activation, since we found that 
the gene expression of the two activity-regulated immediate early genes, Arc and Npas4, was 
significantly increased after the NOR test independently from the CMS exposure and also in 
rats that were exposed for the same time to the empty arena (ie. Sham group). 
We, thus, focused on newly synthesized proteins at synaptic levels because is controlled by 
NMDA and mTOR activation (Marin et al., 1997;Scheetz et al., 2000;Chotiner et al., 
2003;Sutton et al., 2007;Park et al., 2008;Buffington et al., 2014) but also seen the role of this 
mechanism in the memory processes. Indeed, up to hundreds of mRNAs are enriched, in the 
dendrites of differentiated neurons, suggesting that mRNA localization is an important 
mechanism used to differentiate the subcellular compartments also at functional levels. 
Moreover, local and specific translation of a subset of these mRNAs can allow rapid and 
synapse-restricted response to neuronal stimulation. Indeed, although translation occurs 
predominantly in the soma of the cell, the components of the translation apparatus are also 
found in more distal compartments of neurons, such as axons and dendrites (Steward and 
Schuman, 2001). 
  50 
 
Local protein synthesis is a very complex and fine regulated mechanism (Besse and Ephrussi, 
2008), associated with synaptic plasticity and memory (Kang and Schuman, 1996;Klann and 
Dever, 2004;Sutton et al., 2007;Gal-Ben-Ari et al., 2012;Taha et al., 2013;Buffington et al., 
2014).  
It is worth to mention that both NMDAR and mTOR activation not only controls translational 
initiation but is also involved in peptide elongation (Gauchy et al., 2002;Browne and Proud, 
2004). Indeed, exposure of cortical neurons to NMDA in the absence of extracellular calcium 
results in increased eEF2 but not eIF2a phosphorylation (Gauchy et al., 2002). Since an 
increase in peEF2 has been exclusively associated with the inhibition of protein synthesis, the 
concomitant role of NMDARs activation in promoting translation initiation and repressing 
elongation may represent a paradoxical scenario. Now, we know that increased activation of 
peEF2 is associated with a decrease in overall protein synthesis but a concomitant increase in 
the protein levels of specific targets (Chotiner et al., 2003;Park et al., 2008;Buffington et al., 
2014). In general, as observed for eIF2a, also the activation of eEF2 decreases general protein 
translation but increases the translation of specific mRNAs (Klann and Dever, 2004). Moreover, 
it has been (Marin et al., 1997;Scheetz et al., 2000;Sutton et al., 2007) demonstrated that 
NMDA-mediated elongation might be considered a more finely regulated mechanism that 
contributes to the proper timing and spatial localization of neuronal translational events (Marin 
et al., 1997;Scheetz et al., 2000;Sutton et al., 2007). 
Moreover, in neurons, eEF2 is regulated in a compartment-specific fashion. Indeed, Sutton and 
colleagues found that NDMAR-dependent miniature synaptic events in hippocampal neurons 
increase dendritic peEF2 (Sutton et al., 2007). Accordingly, in vivo, there are higher levels of 
peEF2 in synaptoneurosomal fraction than in total cell homogenate (Belelovsky et al., 2005) 
and in dissociated hippocampal neurons, long-term treatment with tetrodotoxin or bicuculline 
has opposing effects on peEF2 in dendrites compare to the soma (Verpelli et al., 2010). 
In line with the activation of the NMDA/mTOR pathways following the behavioral test in 
control rats, we found that the peEF2/eEF2 ratio was significantly increased in no stress rats, 
suggesting possible changes in the translation of specific mRNAs. Accordingly, the 
involvement of eEF2 in memory and learning was already reported in different taste-learning 
paradigms in physiological conditions (Gal-Ben-Ari et al., 2012;Taha et al., 2013). Moreover, 
chronic administration of the selective serotonin reuptake inhibitor, fluoxetine, induced eEF2 
phosphorylation in the prefrontal cortex, hippocampus and dentate gyrus (Dagestad et al., 
2006). 
Interestingly, after the NOR test, we found an increase of OPHN-1 and BMAL1 in no stress 
rats, but not in CMS rats, while ARC protein levels were unchanged, suggesting that the gene-
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specific translation control by peEF2, as indicated for peIF2a, depends on the regulatory 
elements in the mRNA namely open reading frames (uORFs). 
Supporting the role of Ophn-1 in cognitive processes, it has been recently demonstrated that its 
silencing in the hippocampus leads to impairment in the novel object recognition test (Di Prisco 
et al., 2014). Moreover, it has been reported that, at synaptic levels, oligophrenin-1 interacts 
with Rev-erba (Valnegri et al., 2011). Since both Bmal1, as Rev-erba, belongs to the circadian 
clock and are involved in the controls of circadian rhythmicity (Lowrey and Takahashi, 2011), 
our results confirm the hypothesis of Valnegri et al. on the influence of circadian rhythms on 
cognitive ability.  
Interestingly, we found a positive and significant correlation between the protein levels of 
pGluN2B, pmTOR and peEF2/eEF2 and the NOR index suggesting that deficits in these 
‘synaptic’ mechanisms may indeed contribute to the cognitive impairment observed in CMS 
rats. 
In summary, our results suggest that the correct performance in a cognitive test is associated 
with the translation of specific mRNAs at synaptic levels and that the cognitive deficits due to 
chronic stress exposure are due to alterations of this mechanism. Moreover, we highlighted a 
fundamental role of the elongation step in the correct cognitive performance. It may be inferred 
that pharmacological intervention able to normalize these alterations might improve cognitive 
function in patients with major depression and stress-related disorders.  
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1.15 Effect of prolonged lurasidone treatment on chronic mild stress-induced 
alterations: a role for glucocorticoid receptor 
Manuscript in preparation 
 
It is well known that psychiatric diseases are characterized by an altered function of the 
hypothalamic-pituitary-adrenal axis (Holsboer, 2000;de Kloet et al., 2005). 
In particular, the HPA axis is controlled by a feedback mechanism that serves as negative 
regulator of the axis’ activity. This system is deregulated in stress-related disorders, including 
major depression, with a disruption of the feedback that lead to high levels of circulating cortisol 
and to an excessive activation of the HPA axis. 
Moreover, since a correct hormonal response is essential for learning and memory processes 
(Sandi et al., 1997) the alterations of this system may contribute to the development of cognitive 
deficits that represents one of the most debilitating symptoms of major depression. Indeed, 
cognitive impairment may persist even when patients are successfully treated with 
antidepressants and remission is achieved, thus representing a residual symptom that reduces 
the everyday performance and causes considerable distress. 
Glucocorticoids hormones act via genomic mechanisms, involving nuclear receptors, as well 
as via non-genomic pathways that require membrane-associated receptors.  
In particular, the genomic action of GRs regulates the transcription of target genes that contain 
in the promoter the glucocorticoid responsive element, including genes playing a key role in 
synaptic plasticity and memory (Datson et al., 2001;Morsink et al., 2006;Datson et al., 2008). 
Furthermore, in the non-genomic pathways, GCs can directly stimulate the release of excitatory 
amino acids, via the synaptic membrane associated receptors, and can regulate mitochondrial 
oxidation and free radical formation through the binding with GRs on the mitochondrial 
membranes (McEwen et al., 2015). 
In the present study, we investigated the changes occurring in the HPA axis following chronic 
stress and their potential involvement in the anhedonic phenotype as well as in the cognitive 
impairment that develop in animals vulnerable to stress exposure (Calabrese et al., 2017). 
Moreover, we evaluated the ability of chronic lurasidone treatment in counteracting the 
behavioral impairment observed in CMS rats and the possible role of the GRs in its effect. The 
molecular analyses were conducted in the dorsal hippocampus, a brain structure highly sensitive 
to stress, which plays an important role in memory formation (Kim and Diamond, 2002). 
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1.15.1 Results 
1.15.1.1 Behavioral characterization of chronically stressed rats treated with lurasidone 
As previously demonstrated (Calabrese et al., 2017), already after one week of chronic stress 
exposure, rats developed an anhedonic phenotype, as indicated by the reduced consumption of 
1% sucrose solution (-7gr, p<0.001 vs no stress/VEH), an effect that persisted for the 
subsequent 6 weeks of CMS (week2: -7.6gr, p<0.001 vs no stress/VEH; week3: -6 gr, p<0.001 
vs no stress/VEH; week4: -7.9, p<0.001 vs no stress/VEH; week5: -7.5, p<0.001 vs no 
stress/VEH; week6: -7.4gr, p<0.001 vs no stress/VEH; week7: -6.8gr, p<0.001 vs no 
stress/VEH).  
After the initial two weeks of CMS protocol, animals that had developed anhedonia were 
randomized in two groups to receive vehicle or lurasidone for five weeks, while continuing 
stress exposure. 
Chronic treatment with lurasidone, in comparison to vehicle administration, did not affect 
sucrose intake in control animals, while starting from the second week of treatment (fifth week 
of stress protocol), the drug significantly increased the sucrose intake in stressed animals 
(week5: +3.2 gr, p<0.05 vs CMS/VEH; week6: +4gr, p<0.05 vs CMS/VEH; week7: +5gr, 
p<0.05 vs CMS/VEH) (fig. 18A). As clearly shown in figure 18B, by quantifying the overall 
result after 7th weeks of CMS, we found a significant effect of stress (F1-80=19.256, p<0.001), 
of the treatment (F1-80=4.322, p<0.05) and a stressXtreatment interaction (F1-80=16.724, 
p<0.001). Indeed, stress exposure significantly decreased sucrose consumption (-6.8gr, 
p<0.001 vs no stress/VEH), effect that was normalized by the lurasidone administration (+5gr, 
p<0.001 vs CMS/VEH).  
Interestingly, in line with previous findings (Calabrese et al., 2017), 7 weeks of CMS led to the 
development of cognitive deficits, as indicated by the significant reduction of the NOR index 
(-30%, p<0.001 vs no stress/VEH). When examining the effect of lurasidone on stress-induced 
deficits in cognition, two-way ANOVA analysis revealed a significant effect of CMS (F1-
40=9.869, p<0.01), of treatment (F1-40=9.688, p<0.01) as well as a stressXtreatment interaction 
(F1-40=6.866, p<0.05). Indeed, the pharmacological treatment completely restored the stress 
mediated-alterations (+42%, p<0.001vs no CMS/VEH) (fig. 18C). 
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Fig. 18: Behavioural characterization of animals exposed to chronic mild stress (CMS) and treated with 
lurasidone (LUR). The data are the mean ± SEM of at least 10 animals. Panel A shows the sucrose intake 
performed every week, while panel B reports the results of the test after 7 weeks of CMS, expressed as 
grams of consumed sucrose. The result of the novel object recognition test is summarized in the panel 
C. ***p<0.001 vs no stress/VEH; #p<0.05, ##p<0.01; ### p<0.001 vs CMS/VEH) (two-way ANOVA 
with repeated measures panel A; two-way ANOVA with PLSD panel B-C). 
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1.15.1.2 Modulation of nuclear GR protein levels and of GR responsive genes by chronic stress 
exposure 
In order to establish whether GR genomic effect contribute to the cognitive performance, we 
evaluated nuclear GR signaling both under resting condition and following the exposure to the 
novel object recognition test in animals expose or not to the CMS paradigm. 
GR receptor in the nuclear compartment was significantly modulated by the stress (F1,41= 4.342, 
p<0.05), by the test (F1,41= 10.624, p<0.01) and by the stressXtest interaction (F1,64= 7.106, 
p<0.05) as revealed by the two-way ANOVA. Indeed, we found that exposure to NOR test 
significantly increased nuclear GR protein levels in non-stressed animals (+96%, p<0.001 vs 
no stress/Naïve), an effect that that was not observed after the task in CMS rats (+9%, p>0.05 
vs no stress/Naïve) (fig. 19A). These results suggest that the cognitive test requires a significant 
translocation of GR into the nucleus, a mechanism that is impaired in CMS rats. Hence, in order 
to establish if the translocation of GRs to the nuclear compartment is associated with the 
transcription of genes containing the GRE in their sequences, we measured the mRNA levels 
of some GR responsive genes, which are known to play a role in stress response and may be 
dysregulated in psychiatric disorders. Interestingly, the modulation of nuclear GR levels was 
paralleled by an upregulation of different GR responsive genes, such as Gadd45b, Sgk-1 and 
Nr4a1, involved in learning and memory. For Gadd45b we found a significant effect of CMS 
(F1,64= 6.926, p<0.05), of the cognitive test (F1,64= 20.461, p<0.001) as well as a stressXtest 
interaction (F1,64= 7.333, p<0.01). Indeed, we found that non-stressed rats exposed to the NOR 
test showed a significant increase of Gadd45b mRNA levels (+96%, p<0.001 vs no stress), as 
compared to naïve rats, an effect that that was not observed in CMS rats exposed to the 
behavioral test (fig. 19B). As shown in figure 19C, two-way ANOVA analysis revealed a 
significant stress (F1,62= 8.141, p<0.01) and test (F1,62= 14.625, p<0.001) effect on Sgk1, with 
its expression being up-regulated by the test only in non-stressed rats (31%, p<0.001 vs no 
stress/Naïve). Similarly, Nr4a1 was significantly affected by the test (F1,38= 5.605, p<0.05) with 
an increase due to the behavioral task (+26%, p<0.05 vs no stress/Naïve) in control animals 
(fig. 19D).  
As shown in figure 19E, we observed a significant effect of the behavioral test (F1,39= 28.408, 
p<0.001) on Dusp1 expression. Indeed, independently by stress exposure, the gene was up-
regulated by the NOR both in non-stressed (+38%, p<0.05 vs no stress/Naïve) and in stressed 
rats (+29%, p<0.05 vs CMS/Naïve).  
Of note, other GR-related genes analyzed, such as Fkbp5 and P11 were not altered by CMS or 
NOR (fig. 19F-G).  
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Fig. 19: Analysis of nuclear GR protein levels and of GR-responsive gene expression in the dorsal 
hippocampus of chronically stressed rats, under resting conditions or after exposure to the novel object 
recognition test (NOR). The data, expressed as the percentage of no stress/Naive (set at 100%), are the 
mean ± SEM of at least 6 animals. * p<0.05, ***p<0.001 vs no stress/Naive, ## p<0.01 CMS/Naive 
(two-way ANOVA with PLSD). 
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1.15.1.3   Modulation of nuclear GR protein levels and of GR-responsive genes by lurasidone 
treatment in chronically stressed rats 
We next examined the modulation of GR levels in the nuclear compartment in CMS rats treated 
with lurasidone and exposed to the NOR test, as compared to CMS rats treated with vehicle, in 
order to assess if the pharmacological treatment was able to exert its beneficial activity at 
behavioral level by restoring the GR genomic pathways, altered by chronic stress. 
As shown before (fig. 19A), exposure to CMS prevents the translocation of GR in the nucleus 
following the cognitive test. Interestingly CMS rats treated with lurasidone showed a significant 
increase of nuclear GR levels upon exposure to the NOR (+36%, p<0.05 vs CMS/VEH), as 
indicated by the two-way ANOVA results (F1,30= 5.060, p<0.05), an effect that resembles what 
we have observed in non-stressed rats during the cognitive performance (see above, fig. 19A). 
Moreover, lurasidone treatment in CMS rats was able to facilitate the transcription of the GR 
responsive genes Gadd45b, Sgk1, Nr4a1 and Dusp1 following the NOR test. Indeed, we found 
a significant effect of the treatment (Gadd45b: F1,52= 7.200, p<0.05; Sgk1: F1,50= 6.672, 
p<0.05), of the test (Gadd45b: F1,52= 16.252, p<0.001 Sgk1: F1,50= 21.344, p<0.001) and a 
significant treatmentXstress interaction (Gadd45b: F1,52= 7.200, p<0.05; Sgk1: F1,50= 6.571, 
p<0.05), with an up-regulation of Gadd45b  (fig. 20B) and Sgk1 (fig. 20C) upon exposure to 
the NOR test only in CMS animals that were chronically treated with lurasidone (+39%, 
p<0.001 vs CMS/LUR/Naïve; +49%, p<0.001 vs CMS/LUR/naïve respectively).  
With respect to Nr4a1, two-way ANOVA revealed a significant effect of the treatment (F1,39= 
5.741, p<0.05) and of the NOR test (F1,39= 5.412, p<0.05). Indeed, Nr4a1 was upregulated 
(+46%, p<0.05 vs CMS/LUR/Naïve) only in CMS/LUR/NOR group (fig. 20D).  
Moreover, as shown in figure 20E, Dusp1 was increased by the NOR independently from the 
pretreatment both in vehicle (+29%, p<0.01 vs CMS/VEH/Naïve) and in lurasidone (+22%, 
p<0.01 vs CMS/LUR/Naïve) treated rats, as confirmed by the results of the two-way ANOVA 
(treatment: F1,39= 6.685, p<0.05; NOR test: F1,39= 21.169, p<0.001, treatmentXtest interaction: 
F1,39= 0.107, p>0.05).  
On the contrary, Fkbp5 and P11 expression was not modulated in all the experimental groups 
nor by the treatment neither by the test (fig 20F-G). 
These results suggest that the correct cognitive performance requires the activation of the 
transcription of genes controlled by the GR genomic pathway. Accordingly, the deficit in the 
cognitive task caused by chronic stress is associated with an alteration of these mechanisms. 
Interestingly, lurasidone normalized the cognitive deficits due to CMS exposure (fig. 18C) by 
restoring the ability of GR to translocate in the nucleus and regulate the expression of key genes. 
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Fig. 20: Analysis of nuclear GR protein levels and of GR-responsive gene expression in the dorsal 
hippocampus of chronically stressed rats treated with lurasidone, under resting conditions or after 
exposure to the novel object recognition test (NOR). The data, expressed as the percentage of no 
stress/Naive (set at 100%), are the mean ± SEM of at least 6 animals. ## p<0.01 CMS/Naïve/VEH; 
§p<0.05, §§p<0.01, §§§ p<0.001 vs CMS/Naïve/LUR (two-way ANOVA with PLSD). 
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1.15.1.4 Modulation of GR non genomic pathway by chronic stress exposure 
Next, we investigated the impact of the chronic stress exposure on the GR non-genomic 
mechanisms in naïve animals as well as in rats tested to the NOR. 
As shown in figure 21A, exposure to CMS produced a significant increase of GR protein levels 
in the membrane fraction (+60% p<0.05 vs no stress/Naïve), as revealed by the two-way 
ANOVA results on stress effect (F1-27=7.440, p<0.05). Moreover, as confirmed by the non-
significant effect of the cognitive test in the two-way ANOVA analysis (p>0.05), the exposure 
to the NOR did not alter GR expression at membrane level, nor in control neither in stressed 
groups. 
The activity of membrane-bound GRs, as described above, involves both synaptic as well as 
mitochondrial mechanism.  
In order to investigate the potential functional activity of GRs in the synaptosomal membranes 
we measured SYNAPSIN-I protein levels, whereas for the mitochondrial counterpart we 
assessed the expression of the subunits 1 (cytochrome oxidase 1, Cox1) and 3 (cytochrome 
oxidase 3, Cox3) of the cytochrome c oxidase, a key enzyme in the mitochondrial respiratory 
chain. 
In line with the increase ‘membrane-bound’ GRs observed in stressed rats, as shown in figure 
21B, we found a significant effect of CMS exposure on phospho Ser603 SYNAPSIN-1 (F1-
30=11.357, p<0.01). Indeed, its levels were up-regulated (+88%, p<0.05 vs no stress/Naive) in 
stressed rats compared to naïve counterpart. These changes were not associated with significant 
alterations of total SYNAPSIN-1 levels (fig. 21C). 
Regarding mitochondrial mechanisms, as suggested by the significant effect in the two-way 
ANOVA (F1-39=6.406, p<0.05), chronic stress exposure produced an increase of Cox3 
expression (+21%, p<0.05 vs no stress/Naive) (fig 21E), as compared to non-stressed animals, 
whereas we did not observe any statistically significant change for Cox1 mRNA levels (fig. 
21D). 
Furthermore, exposure to the NOR test did not induce any significant modification nor of the 
membrane-bound GR protein levels, neither of the synaptic and mitochondrial downstream 
effectors (fig. 21, panel A,B,C,D,E), indicating that all the modulations observed in the non-
genomic pathway were mainly driven by the chronic stress, independently from the cognitive 
task exposure. 
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Fig. 21: Analysis of membrane-bound GR, phospho SYN-I Ser603 protein levels and Cox1 and Cox3 
mRNA levels in the dorsal hippocampus of chronically stressed (CMS) rats exposed to the novel objet 
recognition test (NOR). The data, expressed as the percentage of no stress/Naive (set at 100%), are the 
mean ± SEM of at least 6 animals. * p<0.05 vs no stress/Naive (two-way ANOVA with PLSD). 
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1.15.1.5   Modulation of GR non genomic pathway by lurasidone treatment in chronically 
stressed rats 
Last, we investigated the impact of the pharmacological intervention with lurasidone on 
membrane-bound GR mechanisms. As shown in figure 22A, we observed a significant effect 
of stress (F1-25=5.880, p<0.05), of treatment (F1-25=4.879, p<0.05) as well as a stressXtreatment 
interaction (F1-25=5.880, p<0.05) for GR protein levels. Indeed, the significant increase of 
membrane GR levels due to CMS exposure (+60% p<0,001 vs no stress/VEH) was normalized 
by the chronic lurasidone treatment (-36%, p<0,01 vs. CMS/VEH).  
Accordingly, the increased of phospho SYN-1 Ser603 (fig. 22B) observed after CMS (+88%, 
p<0.01 vs CMS/VEH) was completely reverted by the pharmacological administration (-58%, 
p<0,01 vs CMS/VEH), as supported by the significant stressXtreatment interaction (F1-
29=8.007, p<0.01) in the two-way ANOVA analysis. Conversely, the treatment did not 
significantly modulate the total form of SYN-I. 
With respect to the mitochondrial targets, the Cox1 expression was modulated by the treatment 
(F1-40=5.880, p<0.05). Indeed, lurasidone downregulated the mRNA levels specifically in non-
stressed animals (-21%, p<0.05 vs no stress/VEH) (fig. 22D). On the contrary, as shown in 
figure 21E, we found a significant effect of the stress (F1-39=4.434, p<0.05) and of the treatment 
(F1-39=4.434, p<0.05) for the Cox3, with an increase of its expression due to CMS exposure 
(+21%, p<0.05 vs no stress/VEH) being normalized by prolonged lurasidone treatment (-20%, 
p<0.01 vs CMS/VEH). 
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Fig. 22: Analysis of membrane GR, phospho SYN-I Ser603 protein levels and Cox1 and Cox3 mRNA 
levels in the dorsal hippocampus of chronically stressed (CMS) rats treated with lurasidone (LUR). The 
data, expressed as the percentage of no stress/Naive (set at 100%), are the mean ± SEM of at least 6 
animals. * p<0.05, **p<0.01, ***p<0.001 vs no stress/VEH; ## p<0.01 vs CMS/LUR (two-way 
ANOVA with PLSD). 
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1.15.2 Discussion 
In this study, we demonstrated that the cognitive deficit caused by the exposure to the CMS is 
associated with an altered activity of both the genomic and of the non-genomic GR pathways. 
Moreover, we found that the ability of prolonged lurasidone treatment to normalize chronic 
mild stress induced-behavioral alterations is accompanied by a normalization of all the GR-
related alterations.  
Interestingly, besides the well-established rescue of the anhedonic phenotype (Calabrese et al., 
2016;Rossetti et al., 2016), lurasidone treatment was also able to normalize the cognitive 
deficits produced by chronic stress exposure. 
Glucocorticoid receptor in the brain are essential players for the response to stressful situations, 
both in term of mood alterations as well as well as for the regulation of memory-related 
mechanisms (Sapolsky et al., 2000), playing a critical role, both in rodents and in human, in 
encoding processing and retaining information of emotional events (Lupien et al., 
2007;McIntyre et al., 2012). Indeed, whereas low-moderate levels of stress stimulate cognitive 
performances and memory formation, severe and chronic stressful experiences can lead to 
cognitive impairments and to the development of psychopathologies (de Kloet et al., 
2005;McEwen et al., 2015). 
The stress response is finely regulated by GCs through complex mechanisms that involve 
different pathways. In particular, GRs are localized in different subcellular compartments thus 
mediating several effects by acting at genomic and non-genomic levels. Accordingly, GCs’ 
actions are critical depending on the timing and on the level of GR expression (Joels et al., 
2006). 
Here, we found that a correct cognitive performance is associated with the activation of the 
genomic pathway, as revealed by the enhanced translocation of the receptor to the nuclear 
compartment and the transcription of some GR-regulated genes, including Gadd45b, Sgk1, 
Nr4a1 and Dusp1 that may facilitate the cognitive performance, since, these GR targets are 
known to be implicated in memory and learning processes. For example, it has been shown that 
Gadd45b KO mice exhibited deficits in the hippocampal long-term memory (Leach et al., 
2012), whereas elevated levels of Sgk and Nr4a1, known to promote memory formation (Hawk 
and Abel, 2011), were found in the hippocampus of rats after learning tasks (Pena de Ortiz et 
al., 2000;Tsai et al., 2002;von Hertzen and Giese, 2005) and transfecting Sgk in the CA1 
hippocampal subfield facilitated spatial memory performance in rats (Tsai et al., 2002). 
Moreover, Dusp1 plays an important role in modulating cellular response to environmental 
stress as an immediate early response gene (Noguchi et al., 1993;Sun et al., 1993). 
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The observation that the induction of nuclear mechanism of GRs in the dorsal hippocampus 
during the cognitive test was completely blunted in stressed rats further supports the role of 
genomic mechanism for the correct performance in the NOR, and it is in line with the findings 
that chronic stress protocols determine important deficits in hippocampal-dependent form of 
memory (Luine et al., 1993;Luine et al., 1994;Yuen et al., 2012). 
Furthermore, we found that 7 weeks of chronic mild stress strongly increased the membrane-
bound GRs that may have implications for synaptic mechanisms and mitochondrial function. 
In particular, the up-regulation of GR protein levels at membrane levels was paralleled by an 
up-regulation of the active form of SYNAPSIN 1, a marker of the functional activity of the 
receptor in the synaptosomal membranes. Accordingly, 21 days of CUS significantly increased 
the density of SYNAPSIN 1 immunoreactive synaptic buttons in the CA3 subfield of the rat 
hippocampus, effect that was restored by the treatment with the GR antagonist Mifepristone 
(Wu et al., 2007). Moreover, since rat model of depression induced by CUS are characterized 
by the corticosterone hypersecretion (Ayensu et al., 1995), these findings are in accordance 
with the report that corticosterone increases the amount of SYNAPSIN I in rat hippocampus 
(Nestler et al., 1981). 
Furthermore, glucocorticoids may also act on GR located on mitochondria membrane and 
regulate the translation of genes involved in the respiratory enzyme biosynthesis (Tsiriyotis et 
al., 1997), such as Cox1 and Cox3, the catalytic subunits of cytochrome c oxidase, the last 
enzyme in the respiratory electron transport chain (Demonacos et al., 1996;Liang et al., 2006). 
Here we found that chronic stress exposure produced an up-regulation of Cox3 mRNA levels, 
but not of the Cox1, in the dorsal hippocampus. In line with the translocation of GR into 
mitochondria under conditions of stress or elevated corticosteroid levels, the expression of 
genes, including Cox1 and Cox3, have been found to be upregulated in the rat hippocampus by 
injection of 300 μg/kg corticosterone (Hunter et al., 2016), whereas Adzic and colleagues found 
a decreased expression of Cox1 and Cox3 in the whole hippocampus, and an increase in the 
prefrontal cortex of rats exposed to 21 days of chronic restraint stress (Adzic et al., 2009). 
Interestingly, lurasidone treatment exerted its beneficial activity at behavioral level, by 
restoring both the anhedonic phenotype and the cognitive alterations, probably acting at 
molecular level by facilitating the nuclear GR translocation, by regulating the concomitant 
transcription of its key genes during ongoing cognitive activity and by normalizing the 
membrane GR content, thus restoring the normal functioning of both phospho SYN-1 Ser603 
and Cox3 gene. These results indicated the useful role of lurasidone in counteracting the 
negative effect driven by chronic stress in the non-genomic mechanisms of GR. 
In summary our findings suggest that the activation of the genomic pathway mediated by GR 
may contribute to the correct cognitive performance, while chronic stress exposure interferes 
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with this mechanism. Moreover, CMS, increasing the availability of GR at membrane levels, 
seems to direct preferentially the action of hormones more towards the non-genomic pathways, 
thus altering synaptic and mitochondrial signaling. In particular, the behavioral deficits we 
observed may be related with both the altered genomic and non-genomic mechanism of GR and 
the dysregulations of these signaling in stressed rats might be indicative of the so-called 
“glucocorticoid resistant” a key feature of depressed patients. 
In addition, we highlight the ability of lurasidone in normalizing the behavioral outcomes, 
induced by CMS exposure, by restoring the modification observed in the GR mediated effects, 
suggesting the potential ability of the drug in modulating dysfunction related with the HPA 
axis. These data provide new insights on the mechanism of action of lurasidone in the context 
of stress-related disorders, indicating that its pharmacological profile may be responsible for 
peculiar adaptive mechanisms that may be critical for the ability to modulate different 
pathologic domains associated with psychiatric disorders. 
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1.16 Effects of chronic stress exposure and lurasidone treatment on HPA axis function: 
focus on DNA methylation  
Unpublished data 
 
DNA methylation of cytosines in cytosine-guanine (CpG) dinucleotides is one of the major 
form of epigenetic modifications that regulates gene expression by affecting the binding of 
transcription factor and regulatory elements (Razin and Riggs, 1980;Bird, 1986). In particular, 
DNA methylation machinery establishes specific methylation patterns during both development 
and adulthood in response to environmental signals and maintains these modifications during 
cell division and after DNA repair (McGowan and Szyf, 2010). 
The epigenetic effects of the environmental stressors have been identified as risk factors for 
different psychiatric disorders, including MDD. Epigenetics are mechanisms that in response 
to social and physical environmental factors, including adverse stimuli, can result in lasting 
changes that affect brain functions and neurobiological processes, including the neuroendocrine 
system (Auger and Auger, 2013). They constitute important mechanisms by which transient 
stimuli can induce persistent changes in gene expression and in behavior (Szyf et al., 
2008;Zovkic et al., 2013). 
Moreover, many antidepressant drugs have been found to influence epigenetic processes, by 
acting as regulators of key mechanisms, thus exerting beneficial effects (Frieling and Tadic, 
2013). 
As previously mentioned, MDD is associated with functional alterations of the HPA axis and 
the gene encoding for the glucocorticoid receptor, Nr3c1, undergoes changes in the methylation 
of its promoter in the context of environmental adversities.  
For example, it has been demonstrated that exposure to early life stress (ELS) can alter the 
expression of Nr3c1, which is sustained by changes in the methylation status of its promoter. 
Such mechanism may contribute to the long lasting consequences of ELS, which may 
eventually lead to the development of mood disorders (Smart et al., 2015). 
Here, on the bases of these observation, we evaluated the functional activity of the HPA axis in 
our animal model of depression, by focusing on DNA methylation mechanism. Furthermore, 
we assessed the possible role of the pharmacological intervention with lurasidone in modulating 
the epigenetic alterations induced by stress exposure.  
With these premises, we aim to assess whether the methylation status of the gene encoding for 
the glucocorticoid receptor Nr3c1 as well as Gadd45b  and the Sgk1, two GR responsive genes, 
could be influenced by chronic stress exposure and by the pharmacological treatment and how 
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the methylation state may affect genes expression. Moreover, we evaluated the long-lasting 
effect of stress exposure by measuring the methylation status of these genes after a period of 
recovery from both chronic stress and the pharmacological treatment.  
In particular, we investigated the methylation status on the promotor region of the Nr3c1 gene 
by describing four CGs methylated in this position. With respect to the two GR responsive 
genes considered, we analyzed the methylation status of the CGs specifically located on the 
glucocorticoid responsive element. Specifically, for Gadd45b, based on literature data, we 
identified on the DNA sequence the possible GRE and we construct the assay in this specific 
sub region, thus measuring the five CGs herein. For Sgk1, Itani and colleagues in 2002, 
demonstrated the presence of a GRE on its DNA sequence (Itani et al., 2002) and in the 
following paragraphs I described the effect of methylation of the two CGs present specifically 
in this region of Sgk1 DNA (for detail see table in the “materials and methods” section). 
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1.16.1 Results 
1.16.1.1 Modulation of Nrc1, Gadd45b mRNA and Sgk1 gene expression in the prefrontal 
cortex of chronically stressed rats treated with lurasidone 
In order to establish the effect of chronic stress and lurasidone treatment on HPA axis activity, 
we analysed the mRNA levels of Nr3c1 and of two GR responsive genes, namely Gadd45b and 
Sgk1.  
The expression level of the gene encoding for the glucocorticoid receptor was not affected by 
stress exposure (F1-36: 2.777), by the pharmacological treatment (F1-36: 0.155, p>0.05), and by 
the stressXtreatment interaction (F1-36: 0.834), as revealed by the two-way ANOVA results (fig. 
23A). However, despite the fact that Nr3c1 was not significantly altered in our experimental 
condition, we investigate the possible modulation of two downstream target of the 
glucocorticoid receptor signalling, Gadd45b and Sgk1. 
As shown in figure 23B, we found a significant effect of stress (F1-37: 4.840, p<0.05) as well as 
of the treatment (F1-37: 6.971, p<0.05) on Gadd45b expression. Indeed, 7 weeks of chronic mild 
stress produced a significant reduction of Gadd45b mRNA levels (-18%, p<0,01 vs no 
stress/VEH) compared to non-stressed rats. On the contrary, prolonged lurasidone treatment 
was able to normalize the CMS-induce downregulation of Gadd45b (+40%, p<0.05 vs 
CMS/VEH). 
Conversely, as shown by the two-way ANOVA results, Sgk1 gene expression was not 
significantly modulated by stress exposure (F1-40: 1.318, p>0.05), by the pharmacological 
treatment (F1-40: 0.362, p>0.05) with no significant stressXtreatment interaction (Sgk1: F1-40: 
0.683, p>0.05) (fig. 23C). 
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Fig. 23: Analysis of Nr3c1, Gadd45b and Sgk1 mRNA levels in the prefrontal cortex of chronically 
stressed rats: modulation by chronic lurasidone (LUR) treatment. The data, expressed as a percentage 
of no stress/VEH animals (set at 100%), are the mean ± SEM of at least six independent determinations. 
*p<0.05 vs no stress/VEH; # p<0.05 vs CMS/VEH (Two-way ANOVA with PLSD).  
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1.16.1.2 Modulation of Nr3c1, Gadd45b and Sgk1 DNA methylation levels in chronically 
stressed rats treated with lurasidone 
The results obtained at transcription levels, in particular the significant downregulation of 
Gadd45b expression induced by chronic stress exposure and the complete normalization due to 
the prolonged lurasidone administration, suggested us to investigated DNA methylation 
mechanism, by which the gene may be regulated by both stress and pharmacological treatment. 
Hence, we assayed the level of Nr3c1, Gadd45b and Sgk1 DNA methylation status in the 
prefrontal cortex of chronically stressed rats treated with lurasidone.  
As shown in figure 24A, the methylation status of Nr3c1 promotor region remained almost 
stable in all the experimental group, without any statistically significant change (no stress/VEH: 
6.3% ± 1.1; no stress/LUR: 5.1%± 1.1; CMS/VEH: 7.1% ± 1.6; CMS/LUR: 5.5% ± 0.9).  
Regarding Gadd45b, we assessed the DNA methylation percentage as the mean of five CGs 
present in the GRE. Interestingly, this region was more methylated in chronically stressed rats 
(13.39% ± 0.7, p<0.05 vs no stress/VEH) as compared to non-stressed group (10.70% ± 0.7) 
(fig. 24B), a data that is in agreement with the reduction observed for Gadd45b mRNA levels 
expression in the same group, as described above (see fig. 23B). Interestingly, prolonged 
lurasidone treatment produced a statistically significant decrease of the methylation percentage 
in chronically stressed rats (11.31% ± 1, p<0.05 vs CMS/VEH), an effect that may contribute 
to restore Gadd45b  mRNA levels in CMS/LUR group (see fig. 23B), with an expression 
similar to the non-stressed group. 
We also analyzed the methylation status of the two CGs present in the GRE sequence on Sgk1 
DNA. However, we didn’t find any statistically significant change in non-stressed groups (no 
stress/VEH: 4.2% ± 0.2; no stress/LUR: 4.4± 0.2) as well as in stressed animals (CMS/VEH: 
3.9 ± 0.2; CMS/LUR: 4.1 ± 0.2) (fig. 24C). 
Moreover, the different grade of methylation of these targets, and in particular the higher % of 
methylation of the Gadd45b, suggests that its modulation may have more functional 
consequences in response to environmental stimuli, as compared to the other genes investigated. 
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Fig. 24: Analysis of Nr3c1, Gadd45b and Sgk1 DNA methylation in the prefrontal cortex of chronically 
stressed rats (CMS): modulation by chronic lurasidone (LUR) treatment. The data, expressed as 
methylation percentage, are the mean ± SEM of the position analysed of at least 10 independent 
determinations. **p<0.05 vs no stress/VEH; # p<0.05 vs CMS/VEH (Two-way ANOVA with PLSD). 
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1.16.1.3 Analysis of Nrc1, Gadd45b mRNA and Sgk1 gene expression in the prefrontal cortex 
of chronically stressed rats treated after a period of recovery: modulation by chronic 
lurasidone (LUR) treatment 
Next, we decided to investigate if the HPA axis function could be altered by CMS exposure 
following a period of recovery. Indeed, while it is known that its activity is compromised by 
chronic stress exposure, little is known about the persistent consequences of prolonged negative 
adversities on the axis activity. 
Hence we investigated the mRNA levels of Nr3c1, Gadd45b and Sgk1 mRNA levels in 
chronically stressed rats (treated with vehicle or lurasidone) after 4 weeks of recovery at the 
end of stress exposure. 
Nr3c1 gene expression, as revealed by the two-way ANOVA analysis, was not significantly 
modulated after the washout by the stress+washout (F1-37: 0.43, p>0.05), by the 
pharmacological treatment+washout (F1-37: 1.237, p>0.05) and there was no interaction 
between the two variables (F1-37: 1.193, p>0.05) (fig. 25A). These data are in line with the 
results obtained immediately at the end of chronic stress procedure (fig. 23A), thus 
corroborating the fact that nor stress exposure, neither the lurasidone administration, influenced 
the expression levels of the glucocorticoid receptor in our experimental condition. 
Regarding Gadd45b, the analysis of the two-way ANOVA showed a significant effect of 
stress+washout (F1-40: 8.968, p<0.01) and of the treatment+washout (F1-40: 4.293, p<0.05) 
without a significant interaction between the two conditions (F1-40: 2.141, p>0.05). 
Accordingly, in stressed rats exposed to a period of washout, independently from the pre-
treatment, we found a significant decrease of Gadd45b mRNA levels (-36%, p<0.01 vs no 
stress/washout), an effect that was also observed in non-stressed rats treated with lurasidone (-
28%, p<0.05 vs no stress/washout) (fig. 25B). This finding suggests that stress exposure has 
long-lasting and detrimental effect on Gadd45b expression. 
On the contrary, with respect to Sgk1, as confirmed by the two-way ANOVA analysis, we did 
not observe any statistically significant effect of the stress+washout (F1-40: 1.318, p>0.05), of 
the pharmacological treatment+washout (Sgk1: F1-40: 0.362, p>0.05) and of the interaction 
(Sgk1: F1-40: 0.683, p>0.05) (fig. 25C). 
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Fig. 25: Analysis of Nr3c1, Gadd45b and Sgk1 mRNA levels in the prefrontal cortex of chronically 
restraint stressed rats (CRS) after 3 weeks of recovery (washout): modulation by chronic lurasidone 
(LUR) treatment. The data, expressed as a percentage of no stress+washout/VEH animals (set at 100%), 
are the mean ± SEM of at least nine independent determinations. *p<0.05 vs no stress+washout/VEH; 
# p<0.05 vs CRS+washout/VEH (Two-way ANOVA with PLSD).  
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1.16.1.4 Analysis of Nr3c1, Gadd45b and Sgk1 DNA methylation levels of chronically stressed 
rats and exposed to a period of recovery: modulation by chronic lurasidone (LUR) 
treatment 
In order to evaluate whether the long-lasting effect of chronic stress exposure were sustained 
by epigenetic mechanisms, we investigated the DNA methylation levels of Nr3c1, 
Gadd45b and Sgk1 after three weeks of recovery from both the stress procedure and the 
pharmacological treatment. 
After three weeks of recovery, Nr3c1 promoter region methylation status was not affected by 
CRS exposure and/or lurasidone treatment (no stress+washout/VEH: 3.9% ± 0.2, p>0.05; no 
stress+washout /LUR: 3.9± 0.4, p>0.05; CRS+washout /VEH: 3.9 ± 0.5, p>0.05; CRS+washout 
/LUR: 5.7 ± 1.1, p>0.05) (fig. 26A). 
On the contrary, as shown in figure 26B, Gadd45b was significantly more methylated after the 
three weeks of stress washout (12.64± 0.5, p<0.05 vs no stress+washout/VEH) as compared to 
non-stressed rats (10.54 ± 0.5), in line with the decreased of Gadd45b mRNA levels (fig. 25B), 
suggesting that this epigenetic mechanism may contribute to the persistent changes observed 
on this GR responsive gene, even after a period of washout. However, lurasidone treatment was 
not able to counteract this long-lasting modulation induced by CRS. 
Similarly, Sgk1 methylation levels were significantly increased after the recovery period from 
CRS (4.4 ± 0.2 vs no stress+washout/VEH), as compared to no stress+washout group (3.8 ± 
0.2) (fig. 26C), even if the Sgk1 mRNA levels were not significantly modulated in our 
experimental conditions (fig. 25C).  
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Fig. 26: Analysis of Nr3c1, Gadd45b and Sgk1 DNA methylation in the prefrontal cortex of chronically 
restraint stressed rats (CRS) after 3 weeks of recovery (washout): modulation by chronic lurasidone 
(LUR) treatment. The data, expressed as methylation percentage, are the mean ± SEM of the position 
analysed of at least 10 independent determinations. *p<0.05 vs no stress+washout/VEH (Two-way 
ANOVA with PLSD). 
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1.16.2 Discussion 
In this section of our study, we provide support to the evidence that chronic stress exposure has 
a direct impact on the DNA methylation and that the pharmacological treatment with lurasidone 
may modulate these epigenetics alterations in rat prefrontal cortex. Furthermore, we found that 
these stress-induced modifications were still present following a period of recovery from stress 
and in our experimental conditions the drug administration was not protective.  
Recent evidence indicates that epigenetic mechanisms, including histone modifications and 
DNA methylation, are involved in the pathophysiology of depression and in the action of 
antidepressants (Krishnan and Nestler, 2008) and that such mechanisms may affect several 
pathways leading to depression-like behaviors in animal models (Massart et al., 2012). In 
particular, cytosine methylation within the CpG islands in critical regulatory regions alters 
genes transcription, without changing their sequences, thus having important functional 
consequences for the regulation of the affected genes (Farrell and O'Keane, 2016). Moreover, 
the dynamic regulation of DNA cytosine methylation extends beyond the developmental 
period, being maintained in adult brain, where its alteration can contribute to psychiatric 
disorders (Moore et al., 2013). 
In the field of epigenetics and MDD, the majority of the studies associated early life adversities 
with long-lasting alterations of DNA methylation of candidate genes for depressive disorders 
(Weaver et al., 2004a;Murgatroyd et al., 2009), notably involved in the regulation of the HPA 
axis activity (Weaver et al., 2004b). Here, we assessed the impact of chronic stress exposure ad 
adulthood, and its possible long-lasting consequences, on the HPA activity, by evaluating the 
involvement of epigenetic mechanisms, in particular DNA methylation, in the dysregulation of 
the HPA axis. Moreover, we also examined the contribution of the pharmacological treatment 
with lurasidone in counteracting molecular abnormalities related with the glucocorticoid 
receptor signaling. 
In our experimental paradigm, nor the Nr3c1 gene expression, neither its methylation were 
perturbed by 7 weeks of chronic mild stress or by lurasidone administration and this status did 
not change after a period of recovery from both stress and the pharmacological treatment. 
Despite we did not find any alteration on the glucocorticoid receptor, its epigenetic 
modification, as link among the HPA axis functionality and stress related disorders, has been 
widely analyzed. Indeed, it has been demonstrated that early life adversities were able to modify 
the methylation status of the Nr3c1, thus leading to long-lasting consequences later in life 
including the development of mood disorders (Smart et al., 2015). Moreover, depressed patients 
have high levels of Nr3c1 methylation (Farrell et al., 2018) and Massart and colleagues found 
altered epigenetic regulators expression in GR-I mice, a genetic model of depression (Massart 
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et al., 2012). Among the downstream targets of GR, we found that 7 weeks of chronic mild 
stress decreased Gadd45b  mRNA levels, indicating that regulatory mechanisms involved in 
the transcription of genes, may be affected by stress exposure, thus altering their expression. 
These results were in line with the findings of Grassi and colleagues who demonstrated that 
chronic mild unpredictable stress produced a significant down-regulation of the demethylase 
Gadd45b mRNA levels in the prefrontal cortex of mice (Grassi et al., 2017). 
Interestingly, this transcriptional change was sustained by epigenetic modification, with an 
overall increase of the methylation percentage at the GRE of Gadd45b, due to stress exposure. 
We hypothesize that chronic stress induced-methylation of these CGs could prevent the binding 
of transcriptional regulatory proteins at the GRE site, thus altering the down-stream activity 
mediated by the HPA axis functioning. Moreover, after three weeks of recovery, we found a 
persistent Gadd45b methylation status due to stress pre-exposure, suggesting an enduring effect 
of chronic stress exposure. Interestingly chronic lurasidone treatment was able to normalize not 
only the CMS induced reduction of Gadd45b expression, but also the changes of the DNA 
methylation status due to chronic stress. These results suggest that lurasidone may exert a 
protective effect toward stress, also by interfering with the epigenetic alterations produced by 
the adverse experience. The finding that chronic lurasidone treatment was able to revert the 
DNA methylation changes when chronically administered during the pathological condition 
represents an important observation in the field of the “epigenetically targeted interventions”, 
to alleviate adverse phenotype (Szyf et al., 2016). Conversely, we did not observe the beneficial 
effect of the drug in the post-treatment period. Indeed, after the cessation of chronic lurasidone 
administration, the long-lasting stress-induced changes in expression and methylation of 
Gadd45b were not normalized by the drug. 
In line with the CMS-modulation of Gadd45b, prolonged stress had persistent consequences 
also on Sgk1 methylation in the CGs of the GRE, independently from lurasidone administration, 
even if the degree of change was minor than the one observed for the Gadd45 b. Accordingly, 
Sgk1 has been identified as DNA methylation biomarker of MDD since its methylation status 
as been found to be altered in the peripheral blood of depressant patients (Numata et al., 2015). 
Our results indicated that chronic stress affected and compromised mainly Gadd45b expression, 
acting at both transcriptional and epigenetic level. These effects persisted even after the 
recovery period, pointing out that Gadd45b  may represent a stable stress-induced molecular 
scar in the rat prefrontal cortex. Moreover, the observation that the methylation status of this 
GR responsive gene was completely reverted by the lurasidone treatment, indicated that 
Gadd45b  may be a candidate marker for pharmacological treatment of stress-related disorders. 
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Furthermore, seen the long-lasting consequence of stress on the methylation profile of both 
Gadd45b and Sgk1, whereas no endurable effect of the drug, our results suggested the need to 
extend the drug administration after the cessation of the stress protocol in order to avoid the 
rebound mechanisms driven by the suspension of lurasidone during the recovery. Thus, it may 
be proposed that the continuation of the treatment, even after the remission, could have a 
beneficial effect in preventing further relapses as well as in acting on the persistent epigenetic 
alterations connected with chronic stress, that may represent scars of vulnerability to the 
pathology recurrence. 
In conclusion, our data highlight that chronic stress exposure results in persistent changes in 
DNA methylation in specific genes related with glucocorticoids signalling and that lurasidone 
acts as a modifier of such mechanisms, suggesting its potential as modulator of the HPA axis 
that is compromised in different psychiatric disorders (de Kloet et al., 2005;Pariante and 
Lightman, 2008). Moreover, these epigenetic alterations may be connected with the behavioural 
deficits we observed in the chronic mild stress animal model of depression, and the rescue of 
these symptoms by lurasidone treatment (Calabrese et al., manuscript in preparation- chapter 
4.2) may be linked with the drug possible properties as “epigenetic modulators”. 
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1.17 Long-term outcomes of chronic restraint stress and lurasidone treatment on brain 
plasticity and responsiveness to an acute challenge 
Unpublished data 
 
Depression has been largely characterized as a recurrent disorder, with approximately 50% of 
patients that experience relapse (Keller, 2003). Indeed, while it is expected that antidepressant 
or other psychotropic drugs used in the treatment of depression may prevent relapse, limited 
knowledge exists on how long-term pharmacological treatments properly work to manage the 
chronic course of the pathology and to maintain their clinical efficacy. 
Exposure to stressful events during adult life may have an adverse impact on the long-term 
course of the disorder and it may increase the response to subsequent stressors. Indeed, it is 
possible that not all the systems impaired by stress are restored during the remission, thus 
leaving ‘scars’ of vulnerability that may facilitate the relapse to the pathology. 
Furthermore, even if at preclinical level chronic stress exposure at adulthood has been widely 
described as environmental factor able to induce depressive phenotype in rodents, limited 
information is available on the long-lasting impact of stress as well as on the mechanisms that 
may promote or prevent relapse. Actually, the effect of stress may not only have persistent 
consequences, but may physiologically be recovered through the activation of dynamic 
processes that help the brain to achieve successful adaptation (McDowell et al., 2015). 
Hence, the main purpose of this experiment was to investigate if and how stress-induced 
changes may persist after a recovery period and to understand the molecular mechanisms that 
may underlie the precipitation of a recurrent episode. Moreover, we aim to establish whether 
such changes can be modulated by the treatment with lurasidone, to better understand if 
pharmacological intervention may lead to a more complete normalization of the molecular 
alterations induced by stress, which may account for a reduced susceptibility to subsequent 
negative events. 
To address these objectives, we exposed adult rats to four weeks of chronic restraint stress and 
we left them to recover for the subsequent three weeks, to identify the functional abnormalities 
that may render them more ‘vulnerable’ under a challenging precipitating condition in the rest 
period. Hence, after the recovery the animals were presented to an acute immobilization stress 
in order to establish differences in molecular responsiveness to the stressful event, in animals 
that were originally exposed to the CRS procedure and had received vehicle or lurasidone 
treatment. We focus our analyses on the prefrontal cortex and dorsal hippocampus, brain region 
primary involved in the stress response and in the integration of information for past with 
present stimuli (Fuster et al., 2000).   
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1.17.1 Results 
1.17.1.1 Analysis of Arc mRNA levels following a period of recovery from chronic restraint 
stress and prolonged lurasidone treatment 
First, we investigated the expression level of the activity-dependent gene Arc, a key element of 
neuronal activation associated with ongoing behavioral activity, to assess neuronal 
responsiveness after three weeks of recovery from chronic restraint stress and lurasidone 
treatment. In the prefrontal cortex (fig. 27A), we found a significant effect of the stress (F1-
39=6.828, p<0.05) and of the treatment (F1-39=7.066, p<0.05). In particular, after the recovery 
period from stress, the expression of the IEG was significantly down-regulated by CRS alone 
(-29%, p<0.01 vs no stress+washout/VEH) in comparison to non-stressed rats. Lurasidone 
treatment significant decreased Arc mRNA levels (-29%, p<0.01 vs no stress+washout/VEH) 
in non-stress rats while no further differences were found in animals exposed to CRS.  
Conversely, in the dorsal hippocampus we did not observe any long-lasting modulation on Arc 
expression, nor by the prolonged stress exposure, neither by the pharmacological treatment (fig. 
27B).  
These results indicated that Arc expression was persistently decreased by stress in the prefrontal 
cortex and that the concomitant treatment with lurasidone was not able to counteract the effect 
of the CRS, probably caused by rebound mechanisms set in motion by drug withdrawal, seen 
the downregulation induced also by the drug in non-stressed animals. 
 
 
Fig. 27: Analysis of Arc mRNA levels in the prefrontal cortex (PFC) and dorsal hippocampus (dHip) of 
chronically stressed rats (CRS), treated with lurasidone (LUR), after 3 weeks of recovery (washout). 
The data, expressed as percentage of no stress+washout, are the mean ± SEM of at least 9 independent 
determinations. **p<0.01 vs no stress+washout/VEH (Two-way ANOVA with PLSD). 
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1.17.1.2 Analysis of total Bdnf and Bdnf long 3’UTR mRNA levels following a period of 
recovery from chronic restraint stress and prolonged lurasidone treatment 
On the basis of our previous studies demonstrating that lurasidone is effective in up-regulating 
the expression of the neurotrophin Bdnf and can restore its alterations as a consequence of the 
exposure to stressful experiences (Fumagalli et al., 2012;Luoni et al., 2015), we investigated 
the long-lasting effect of chronic stress exposure and of lurasidone administration on the 
expression of both total Bdnf and Bdnf long 3’UTR. In the prefrontal cortex, as shown in figure 
28A, two-way ANOVA revealed a significant effect of the stress (F1-39=11.071, p<0.05) on the 
total form of the neurotrophin. Indeed, we found that animals exposed to CRS showed a 
decrease of total Bdnf mRNA levels after 3 weeks wash-out (-35%, p<0.01 vs no 
stress+washout/VEH), even when the animals were chronically treated with lurasidone during 
the stress exposure. On the contrary, Bdnf long 3’UTR pool of transcripts were not modulated 
in any experimental groups (fig. 28B).  
In the dorsal hippocampus, we did not find any significant change of total Bdnf and Bdnf long 
3’UTR mRNA levels after the wash-out from stress or lurasidone treatment (figure 28 C-D).  
These results suggest that chronic restraint stress appear to have a stable detrimental effect on 
the expression of the total form of the neurotrophin mainly in the prefrontal cortex, whereas the 
dorsal hippocampus is less vulnerable to stress pre-exposure in term of Bdnf expression. 
Furthermore, prolonged lurasidone administration during stress exposure was not able to 
prevent the downregulation of Bdnf expression in CRS rats following a period of washout 
(recovery).  
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Fig. 28: Analysis of total Bdnf and Bdnf long 3’UTR mRNA levels in the prefrontal cortex (PFC) and 
dorsal hippocampus (dHip) of chronically stressed rats (CRS), treated with lurasidone (LUR), after 3 
weeks of recovery (washout). The data, expressed as percentage of no stress+washout, are the mean ± 
SEM of at least 9 independent determinations. **p<0.01 vs no stress+washout/VEH (Two-way ANOVA 
with PLSD).  
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1.17.1.3 Analysis Gadd45b and Sgk1 mRNA levels following a period of recovery from chronic 
restraint stress and prolonged lurasidone treatment 
In the prefrontal cortex, as describes above (see paragraph 4.3.1, figure 23), Gadd45b 
expression was significantly downregulated by the chronic restrain stress protocol and by 
lurasidone in non-stressed rats and in CRS group the drug did not alter the stress effect. 
Conversely, nor the stress, neither the treatment had persistent effect on Sgk1 mRNA levels. 
In the dorsal hippocampus, (fig. 29A), similarly to what observed in PFC, two-way ANOVA 
revealed a significant effect of the stress (F1-40=6.665, p<0.05) on Gadd45b. Indeed, we found 
that animals exposed to CRS showed a decrease of Gadd45b levels after 3 weeks of wash-out 
(-24%, p<0.01 vs no stress+washout/VEH), even when the animals were chronically treated 
with lurasidone during the stress exposure. Furthermore, lurasidone induced a significant 
persistent downregulation also in non-stressed rats (-18 %, p<0.05 vs no stress+washout/VEH). 
On the contrary, in dHip, Sgk1 was not modulated in any experimental groups (fig. 29B).  
These results suggest that chronic restraint stress have a stable detrimental effect on Gadd45b 
both in the prefrontal cortex and in dorsal hippocampus and that lurasidone was not able to 
counteract the stress effect, whereas Sgk1 was not affected by the experimental conditions. 
 
 
Fig. 29: Analysis of Gadd45b and Sgk1 mRNA levels in the dorsal hippocampus (dHip) of chronically 
stressed rats (CRS), treated with lurasidone (LUR), after 3 weeks of recovery (washout). The data, 
expressed as percentage of no stress+washout, are the mean ± SEM of at least 9 independent 
determinations. * p<0.05, **p<0.01 vs no stress+washout/VEH (Two-way ANOVA with PLSD). 
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1.17.1.4 Analysis of the effects produced by an acute restraint stress on Arc mRNA levels after 
a period of recovery from chronic restraint stress and prolonged lurasidone treatment 
To evaluate if stress exposure and/or lurasidone treatment may alter the ability to respond to a 
challenging environmental stimulus, we next examined the effects of an acute restraint stress 
on the IEG Arc at the end of the 3 weeks of washout.  
In prefrontal cortex (fig. 30A), we found that, independently from the CMS and the 
pharmacological treatment, the acute stress (restraint stress: F1-79=91.453, p<0.001, three-way 
ANOVA analysis), produced an increase of Arc in all groups (no stress+wash/VEH/restraint:+ 
74 %, p<0.001 vs no stress+wash/VEH/naive; no stress+wash/LUR/restraint: +170%, p<0.001 
vs no stress+wash/LUR/ naive; CRS+wash /VEH/restraint: +138% , p<0.001 vs CRS+wash 
/VEH/naive; CRS+wash /LUR/restraint: +163%, p<0.001 vs CRS+wash /LUR/naive) in 
comparison with naive counterparts, suggesting that after the washout period, nor the treatment 
neither the CRS have long-lasting impact on the response to the acute challenge in this brain 
region. 
In dorsal hippocampus (fig. 30B), we found a significant effect of the acute stress (F1-79=25.035, 
p<0.001) and of the treatment (F1-79=4.380, p<0.001). Indeed, exposure to the acute restraint 
stress increased  Arc gene expression in non-stressed rats (+33 %, p<0.001 vs no 
stress+wash/VEH/Naive) as well as in CRS rats treated with vehicle (+54%, p<0,001 vs 
CRS+wash /VEH/Naive) or with lurasidone (+43%, p<0,001 vs CRS+wash /LUR/Naive), but 
not in non-stressed rats treated with the drug (+15%, p>0,05 vs no stress+wash /LUR/Naive).  
All in all, in both brain regions considered, acute stress exposure after a period of washout from 
chronic stress, produced a neuronal activation similar to control rats, without any significant 
effect of lurasidone treatment. 
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Fig. 30: Analysis of Arc mRNA levels in the prefrontal cortex (PFC) and dorsal hippocampus (dHip) of 
chronically stressed rats (CRS), treated with lurasidone (LUR), and exposed to an acute challenge 
(restraint) after 3 weeks of recovery (washout). The data, expressed as percent change of animals 
exposed to the acute stress vs. their sham counterpart, are the mean ± SEM of at least 9 independent 
determinations. *p<0.05, ***p<0.001 vs no stress+washout/VEH/Naïve; §§§ p<0.001 vs no 
stress+washout/LUR/Naïve; ### p<0.001 vs CRS+washout/VEH/Naïve; $$ p<0.01, $$$ p<0.001 vs 
CRS+washout/LUR/Naïve (Three-way ANOVA with PLSD).  
  86 
 
1.17.1.5 Analysis of the effects produced by an acute restraint stress on total Bdnf and Bdnf 
long 3’UTR mRNA levels after a period of recovery from chronic restraint stress and 
prolonged lurasidone treatment 
We also assessed the effects of the acute challenge following the 3 weeks of recovery on total 
Bdnf and Bdnf long 3’UTR expression. 
In the prefrontal cortex, we found a significant increase of the total form of the neurotrophin 
(fig. 31A) due to the acute stress in control rats previously treated with lurasidone (+32%, 
p<0.05 vs No stress+wash /LUR/Naive), as compared to the naïve counterpart, whereas no 
modification was observed in rats pre-exposed to CRS. The pool of Bdnf transcripts with the 
long 3’UTR was modulated by the acute stress (F1-79=40.846, p<0.001 three-way ANOVA 
results) with a significant treatmentXrestraint interaction (F1-79=4.140, p<0.05). Indeed, long 
3’UTR Bdnf mRNA levels were significantly up-regulated in non-stressed rats treated with 
vehicle (+63 % p<0.001 vs no stress+wash/VEH/Naïve) and lurasidone (+74 % p<0.01 vs no 
stress+wash/LUR/Naïve) and in chronically stressed rats administered with lurasidone (+124%, 
p<0,001 vs CRS+wash /LUR/Naive), but not in the CRS group treated with vehicle (+34%, 
p>0.05 vs CRS+wash /VEH/Naive). Interestingly, the pharmacological treatment enhanced the 
response to the challenge, mainly in stressed rats, thus suggesting a potential protecting effect 
of lurasidone administration in the prefrontal cortex (fig. 31B). 
On the contrary, in dorsal hippocampus, we found an overall downregulation of the 
neurotrophin following the acute challenge. Indeed, total Bdnf was regulated by stress exposure 
(F1-80=8.001, p<0.05) and its expression was decreased by the acute stress, specifically in CRS 
rats treated with lurasidone (-20%, p<0.05 vs CRS+wash /LUR/Naive) (fig. 31C). Similarly, as 
shown in figure 31D, the acute restraint stress decreased Bdnf long 3’UTR  gene expression not 
only in non-stressed rats treated with Lurasidone (-18%, p<0.05 vs no stress+wash/LUR/Naïve) 
but also in CRS rats treated with vehicle (-15%, p<0,05 vs CRS+wash/VEH/Naïve) or with 
lurasidone (-14%, p<0,05 vs CRS+wash /LUR/Naive), as confirmed by three-way ANOVA 
(F1-80=16.081, p<0.05).  
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Fig. 31: Analysis of total Bdnf and Bdnf long 3’UTR mRNA levels in the prefrontal cortex (PFC) and 
dorsal hippocampus (dHip) of chronically stressed rats (CRS), treated with lurasidone (LUR), and 
exposed to an acute challenge (restraint) after 3 weeks of recovery (washout). The data, expressed as 
percent change of animals exposed to the acute stress vs. their sham counterpart, are the mean ± SEM 
of at least 9 independent determinations. *p<0.05 vs no stress+washout/VEH/Naïve; § p<0.05, §§ 
p<0.01 vs no stress+washout/LUR/Naïve; # p<0.05 vs CRS+washout/VEH/Naïve; $ p<0.05, $$$ 
p<0.001 vs CRS+washout/LUR/Naïve (Three-way ANOVA with PLSD). 
  
  88 
 
1.17.1.6 Analysis of the effects produced by an acute restraint stress on Gadd45b and Sgk1 
mRNA levels after a period of recovery from chronic restraint stress and prolonged 
lurasidone treatment 
Next, we decided to investigate the expression levels of two activity-dependent immediate early 
genes, Gadd45ß and Sgk-1, which have different implications for the rapid neuronal response 
to stress, since their transcription is strictly related to the activation of the glucocorticoid 
receptor signaling. 
In the prefrontal cortex, independently from CRS exposure and pharmacological treatment, the 
acute stress produced a significant increase of Gadd45b mRNA levels, as compared to rats 
under resting conditions (+51 %, p<0.001 vs no stress+wash/VEH/Naïve; +110%, p<0.001 vs 
no stress+wash/LUR/Naïve; +55%, p<0.01 vs CRS+wash/VEH/Naïve; +74%, p<0.01 vs 
CRS+wash/LUR/Naïve), as confirmed by the acute restraint significant effect (F1-80=75.196, 
p<0.001) (fig. 32A).  
Similarly, the acute challenge produced a significant up-regulation of Sgk1 mRNA levels in 
both non-stressed (VEH: 100%, p<0.001 vs no stress+wash/VEH/Naïve; LUR: +245%, 
p<0.001 vs no stress+wash/LUR/Naïve) and chronically restraint stressed animals (VEH: 
+105%, p<0.001 vs CRS+wash/VEH/Naïve; LUR: +75%, p<0.01 vs CRS+wash/LUR/Naïve ) 
(fig. 32B), and these effects appear to be larger in no stress rats treated with lurasidone, as 
confirmed by the three-way ANOVA results (restraint: F1-78=120.016, p<0.001; stressXrestraint 
interaction: F1-78=9.091, p<0.01; stressXtreatmentXrestraint interaction: F1-78=6.228, p<0.05), 
suggesting that lurasidone may exert a positive sustained effect on the acute stress-dependent 
modulation of Sgk1, mainly in non-stressed rats, thus indicating that stress was able to limit the 
lurasidone induced-changes. 
When investigating the dorsal hippocampus, we found that the acute challenge up-regulated 
Gadd45b  expression in non-stressed rats treated with Lurasidone (+42%, p<0,001 vs no 
stress+wash/LUR/Naïve) as well as in chronically stressed animals treated with vehicle or with 
lurasidone (+49%, p<0,001 vs CRS+wash/VEH/Naïve; +57%, p<0,001 vs 
CRS+wash/LUR/Naïve, respectively), accordingly to the three-way ANOVA (F1-80=57.724, 
p<0.05) (fig. 32C). 
In line with what observed for Gadd45b, we found an effect of the acute stress on Sgk1 (F1-
80=149.984, p<0.001), with an up-regulation of its expression in all the experimental groups 
exposed to the challenge (+129 %, p<0.001 vs no stress+wash/VEH/Naïve; +127%, p<0.001 
vs no stress+wash/LUR/Naïve; +84%, p<0.01 vs CRS+wash/VEH/Naïve; +136%, p<0.01 vs 
CRS+wash/LUR/Naïve), as compared to their naïve counterparts (fig. 32D). In summary, these 
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results suggest that, in this brain region, the up-regulation of these two activity dependent genes, 
following the acute challenging stress, is not altered by previous chronic stress exposure.  
 
 
Fig. 32: Analysis of Gadd45ß and Sgk-1mRNA levels in the prefrontal cortex (PFC) and dorsal 
hippocampus (dHip) of chronically stressed rats (CRS), treated with lurasidone (LUR), and exposed to 
an acute challenge (restraint) after 3 weeks of recovery (washout). The data, expressed as percent 
change of animals exposed to the acute stress vs. their sham counterpart, are the mean ± SEM of at least 
9 independent determinations. ***p<0.001 vs no stress+washout/VEH/Naïve; §§§ p<0.001 vs no 
stress+washout/LUR/Naïve; ## p<0.01, ### p<0.001 vs CRS+washout/VEH/Naïve; $$ p<0.01, $$$ 
p<0.001 vs CRS+washout/LUR/Naïve (Three-way ANOVA with PLSD). 
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1.17.2 Discussion 
In this work we demonstrated that chronic restraint stress produces protracted molecular 
changes that may be found also following a period of recovery. Nevertheless, we highlighted 
the ability of the prefrontal cortex and dorsal hippocampus to display plasticity to deal with 
challenging condition, in term of neuronal activation and neuroplastic mechanisms, when the 
animals were exposed to an acute stress after a wash-out period from CRS. However, the 
concomitant treatment with lurasidone did not modify the response to the acute challenge in 
our experimental conditions. 
Despite the majority of depressed patients may achieve remission following successful 
pharmacological treatment, there is a high percentage who experience relapse, usually as a 
consequence of environmental adversities. Furthermore, around 30% of MDD did not respond 
to pharmacological treatments (Vos et al., 2004;Rush et al., 2006), underlying the need to 
identify novel therapies as well as new pharmacological targets to prevent the relapse.  
On these bases, we investigated the post-stress period and the ability of the brain the react to a 
subsequent challenge, in order to identify long-lasting stress-induced changes, and to 
investigate the ability of lurasidone to improve such alterations. 
After three weeks of washout from stress and lurasidone, the activity dependent gene Arc, an 
important target in neuroadaptation (Tzingounis and Nicoll, 2006), was significantly decreased 
in the prefrontal cortex of stressed rats, an effect that was observed after 11 days of chronic 
restraint protocol (Ons et al., 2010), suggesting a persistent effect of stress on Arc expression.  
With regard to neuroplasticity, the detrimental effect of chronic stress on the neurotrophin Bdnf 
in animal models of depression is well established (Duman and Monteggia, 2006;Calabrese et 
al., 2009;Calabrese et al., 2014). Here, we demonstrated that chronic restraint stress had a long-
lasting, enduring negative effect on the total form Bdnf in the prefrontal cortex, which was 
present even after three weeks of washout, suggesting that the effects produced by stress may 
persist well beyond the end of the adverse experience. On the contrary, in the dorsal 
hippocampus, 21 days following the end of the stress we did not observe any changes of both 
total Bdnf and Bdnf long 3’UTR pool of transcripts, in line with the findings corroborated by 
other groups at transcriptional (Lakshminarasimhan and Chattarji, 2012) and translational level 
(Xu et al., 2004). 
Despite the fact that chronic treatment with lurasidone is able to normalize the changes induced 
by stress on Bdnf expression (Fumagalli et al., 2012;Luoni et al., 2015), here we show that, 
following three weeks of washout from the end of stress or drug administration, lurasidone did 
not exert enduring protective effects in the PFC of CRS rats, suggesting that the drug was 
inefficient in preventing the neuroplastic alterations induced by stress. One possible caveat for 
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these results is that the sudden interruption from lurasidone treatment may generate a sort of 
‘withdrawal’ that has a negative impact on neuroplasticity. Hence, it may be interfered, that the 
drug could exert long-lasting beneficial effect if not interrupted.  
In the prefrontal cortex, after the recovery, both the treatment and stress exposure decreased 
Gadd45b expression with respect to control animals, in line with the downregulation of 
Gadd45b in the PFC that has been detected following the chronic mild unpredictable stress 
protocol (Grassi et al., 2017). Our result, interestingly, indicated the endurable consequence of 
4 weeks of CRS procedure on Gadd45b expression.  
Furthermore, in this brain region, as suggested above, lurasidone treatment may produce 
rebound mechanisms probably set in motion by drug withdrawal, since Arc and Gadd45b 
mRNA levels were downregulated after 3 weeks of the treatment interruption also in non-
stressed animals. Instead, we did not find endurable effects of the stress in the dorsal 
hippocampus, indicating that during the washout period, some systems may be activated 
specifically in this brain area to counteract the persistent consequences of negative stressors. 
Accordingly, different studies demonstrated that the hippocampus appear to “recover” as weeks 
pass from the end of the chronic stress (Hoffman et al., 2011;Ortiz et al., 2014;Ortiz et al., 
2015;Ortiz et al., 2018) and that the recovery of the depressive like behavior, induced by CMS, 
was achieved after 4 weeks of washout (Alves et al., 2017). 
Next, in order to assess if the physiological improvement of the post-stress wash-out period 
may influence the response to a subsequent acute challenge, we exposed rats to one hour of 
acute restraint stress, the same type of stress rats were subjected during the four weeks of CRS, 
to investigate if the memory of the experienced stressors may impact on brain responsiveness 
after recovery. Furthermore, we evaluated the possible protective effect of the lurasidone pre-
administration.  
When we measured Arc expression, independently from the stress and the treatment, in both 
prefrontal cortex and dorsal hippocampus, we observed a rapid and strong upregulation of the 
IEG, in response to the challenge. On the contrary, the downregulation of Bdnf in the post-stress 
rest period appeared to inhibit PFC activation: indeed, both the total and long 3’ UTR Bdnf 
were not enhanced by the acute stress, suggesting an impairment in the neurotrophin-ability to 
cope with the challenging situation due to the long-lasting detrimental effect of CRS.  
Interestingly, chronically stressed rats treated with lurasidone showed enhanced response to the 
challenge, thus suggesting a potential persistent protecting effect of the drug in the prefrontal 
cortex. Conversely, the dorsal hippocampus appeared to be impaired by the acute restraint, with 
in particular Bdnf long 3’ UTR being down-regulated independently from the stress and 
treatment, indicating a lasting negative sensitization to the novel stressor. 
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Finally, the rapid stress neuronal response, in term of the expression of the two activity-
dependent immediate early genes, Gadd45ß and Sgk1, was not prevented by the CRS in both 
the brain regions, independently from the treatment, indicating that their up-regulation, in 
response to new stimuli, was not impaired after the recovery. Moreover, the massive increase 
of Sgk1 in non-stressed rats treated with lurasidone suggested that the drug can exert a positive 
sustained effect on the acute stress-dependent modulation of Sgk1expression, mainly in PFC. 
Taken together, this study indicates that the prefrontal cortex was mainly implicated in the 
adaptation to stressors, exerting its ability to display plasticity after the post-stress wash-out 
period, in particular by adequately reacting to a subsequent acute stress exposure in term of the 
activity-dependent immediate early genes Arc, Gadd45ß and Sgk1, in line with the notions that 
PFC is a brain region with high levels of structural and functional plasticity, that permits itself 
to modify brain functioning by internalizing behavioral experiences (McEwen and Morrison, 
2013). In particular, these results suggest that the recovery period allowed the rats to rescue 
some chronic alterations produced by the prolonged stress exposure, implicating that the rapid 
neuronal activation had returned to a “previous state”, independently from lurasidone. Despite 
of that, the long-lasting negative effect of the chronic stress on the neurotrophin Bdnf interfered 
with the ability of the PFC to cope with a challenging condition, thus leading to the lack of 
response, in term of Bdnf, following the acute challenge. 
In conclusion, we highlight modification, induced by chronic stress, of distinct systems in the 
two areas considered, and their different adaptations and support during the recovery period. 
Moreover, these results reveal the complexity of the plastic mechanisms set in motion to cope 
with challenges, mainly when the system was previously impaired, adding critical new 
information in the field of better understanding the ways to promote mechanisms of adaptive 
plasticity. 
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1.18 Effect of acute stress on the cognitive performance: a role for neuroplastic 
mechanisms 
Unpublished data 
 
The brain is the primary organ that response to stressful stimuli in order to cope with 
homeostatic challenges. It is well documented that exposure to mild and brief stressors provide 
beneficial advantages in a short-term, period by activating protective functions or by preparing 
the organism to react with external demands. Furthermore, when the stress is short, it can have 
positive effects on memory (Joels et al., 2006) and even be fundamental for good learning 
(Sandi and Rose, 1994;Sandi et al., 1997). Here, to determine the consequences of an acute 
stress on memory processes, we tested adult rats in a cognitive task at different time points, in 
order to have a time-course of the effect of the stress. Specifically, rats were exposed to the 
novel object recognition test 1 hour, 4 hours and 24 hours after the acute challenge.  
Moreover, at molecular level, we focus on neuronal activation, in terms of Arc and Gadd45b 
expression, and on neuroplastic mechanisms, by measuring the neurotrophin Bdnf, since it is 
well known the strong relationship between acute stress response and neuroplasticity (Calabrese 
et al., 2009). The analyses were conducted after the exposure to the acute stress but also after 
the test, in order to evaluate if the behavioral phenotype is associated with alterations due to the 
challenge per sè, or/and to modification of the system set in motion during the cognitive 
performance. 
The molecular study was performed in prefrontal cortex and dorsal hippocampus, two brain 
regions known to be connected with working memory and with the response systems implicated 
in the coping ability with external and internal challenges. 
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1.18.1 Results 
1.18.1.1 Effect of one hour of acute restraint stress on the cognitive performance in the novel 
object recognition (NOR) test 
As shown in figure 33, one-way ANOVA revealed a significant stress effect (F3-24:3.790, 
p<0.05). Animals exposed to the novel object recognition test performed significantly better 
when examined at 1hour (+100%, p<0.05 vs no stress-NOR) and at 4 hours (+76%, p<0.05 vs 
no stress-NOR) post- stress compared to control animals. This difference disappeared 24 hours 
after the acute stress, when rats performed like the non-stressed rats (+1%, p>0.05 vs no stress-
NOR).  
These results indicate that acute stress facilitates working memory within the time frame of 1 
to 4 hours. 
 
 
Fig. 33: Effect of one hour of acute restraint stress on the cognitive performance, measured in the novel 
object recognition test, 1h (restraint-1h), 4h (restraint-4h) and 24h (restraint-24h) after the end of the 
challenge. The data, expressed as discrimination index % of no stress rats (set al 100%), are the mean 
of at least 7 independent determinations ± SEM. * p<0.05, vs no stress (one-way ANOVA with PLSD). 
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1.18.1.2 Effect of one hour of acute restraint stress on Arc expression in rat prefrontal cortex 
and dorsal hippocampus 
Focusing on the immediate early gene Arc, we evaluated the effect of neuronal activation, in 
response to one hour of acute restraint stress to establish its possible contribution to the 
behavioral results observed.  
In prefrontal cortex (fig. 34A) we found a significant effect of stress (F3-22:9.952, p<0.001), 
with Arc mRNA levels being up-regulated 1 hour (+173%, p<0.001 vs no stress), 4 hours (+ 
74%, p<0.05 vs no stress) and 24 hours (+87%, p<0.05 vs no stress) after the end of the acute 
challenge, in comparison to non-stressed group.  
Similarly, in the dorsal hippocampus (fig. 34B), one-way ANOVA reveled a significant effect 
of the stress (F3-22:3.813, p<0.05). Accordingly, Arc gene expression increased in restraint-1h 
group (+38%, p<0.05 vs no stress), and restraint 24h (+40%, p<0.05 vs no stress) with respect 
to control animals, whereas the slight increase in restraint-4h did not reach the statistical 
significance (+20, p>0.05 vs no stress). 
These results, in both the brain regions, indicated that acute stress caused a rapid induction of 
the IEGs expression that last until 24 hours later the one hour of restraint. 
 
 
Fig. 34: Analysis of Arc mRNA levels in the prefrontal cortex (PFC) and dorsal hippocampus (dHip) of 
acutely stressed rats sacrificed 1h (restraint-1h), 4h (restraint-4h) and 24h (restraint-24h) after the end 
of the challenge. The data, expressed as % of no stress rats (set al 100%), are the mean of at least 5 
independent determinations ± SEM. * p<0.05, *** p<0.001 vs no stress (one-way ANOVA with PLSD). 
  
  96 
 
1.18.1.3 Effect of one hour of acute restraint stress on Gadd45b expression in rat prefrontal 
cortex and dorsal hippocampus 
Next, we assessed the modulation of the acute challenge on the activity-dependent immediate 
early gene Gadd45b. In both the brain regions, we found a significant effect of stress (PFC: F3-
22: 22.178, p<0.001; dHip F3-22: 13.545, p<0.001, one-way ANOVA),with an up-regulation of 
Gadd45b specifically one hour after the stress (PFC: +115%, p<0.001 vs no stress; dHip: +63%, 
p<0.001) (fig. 35A-B), whereas only in dHip the modulation is still present 24h after the stress 
(+25%, p<0.05 vs no stress) (fig. 35B).  
The results obtained, indicated that the effect of the restrain protocol on Gadd45b is transient, 
probably partially contributing to the behavioral outcome. 
 
 
Fig. 35: Analysis of Gadd45b mRNA levels in the prefrontal cortex (PFC) and dorsal hippocampus 
(dHip) of acutely stressed rats sacrificed 1h (restraint-1h), 4h (restraint-4h) and 24h (restraint-24h) 
after the end of the challenge. The data, expressed as % of no stress rats (set al 100%), are the mean of 
at least 5 independent determinations ± SEM. * p<0.05, *** p<0.001 vs no stress (one-way ANOVA 
with PLSD). 
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1.18.1.4 Effect of one hour of acute restraint stress on total Bdnf and Bdnf isoform IV 
expression in rat prefrontal cortex and dorsal hippocampus 
In the prefrontal cortex, the one-way ANOVA analysis showed a significant effect of stress (F3-
22: 8.523, p<0.01) on total Bdnf expression (fig. 36A). Indeed, total Bdnf mRNA levels 
significantly increased 1h after the stress (+66%, p<0.001 vs no stress). 
Similarly, acute restraint stress significantly modulated Bdnf isoform IV (F3-22: 20.343, 
p<0.001). Accordingly, one hour of stress induced an up-regulation at 1h (+149%, p<0.001 vs 
no stress) and 24h (+46%, p<0.05 vs no stress) (fig. 36B).  
In dorsal hippocampus, we did not find a statistic effect of stress in the one-way ANOVA 
analysis (F3-22: 2.242, p>0.05) for total Bdnf. Nevertheless, as shown in figure 36C, 24 hours 
after the acute challenge total Bdnf were significantly increased in comparison with non-
stressed rats (+59%, p<0,05 vs no stress). 
In this brain region, the levels of the Bdnf isoform IV (fig. 36D) were not significantly affected 
by the stress (F3-22: 0.171, p>0.05).  
These results indicate that the improvement in the cognitive performance observed one hour 
after the acute stress required the up-regulation of Bdnf specifically in the PFC.  
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Fig. 36: Analysis of total Bdnf and Bdnf isoform IV mRNA levels in the prefrontal cortex (PFC) and 
dorsal hippocampus (dHip) of acutely stressed rats sacrificed 1h (restraint-1h), 4h (restraint-4h) and 
24h (restraint-24h) after the end of the challenge. The data, expressed as % of no stress rats (set al 
100%), are the mean of at least 5 independent determinations ± SEM. * p<0.05, *** p<0.001 vs no stress 
(one-way ANOVA with PLSD). 
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1.18.1.5 Effect of the cognitive test exposure after the acute restraint stress: focus on Arc 
expression in rat prefrontal cortex and dorsal hippocampus 
In prefrontal cortex (fig. 37A), we found a significant effect of the stress (F3-50: 4.678, p<0.01), 
of the cognitive test (F1-50: 104.936, p<0.001) and of the stressXtest interaction (F3-50: 6.375, 
p<0.01). Indeed, the exposure to NOR test induced a significant increase of Arc not only in 
non-stressed rats (+264%, p<0.001 vs no stress/Naïve) but also in the groups tested 4 hours 
(+96%, p<0.001 vs restraint-4h/Naïve) and 24 hours (+173%, p<0.001 vs restraint-24h/Naïve) 
after the acute challenge. Actually, one hour after the acute challenge, the exposure to the 
cognitive test did not lead to an additional increase of Arc mRNA levels (+25%, p>0.05 vs 
restraint-1h/Naïve), thus implicating that at this time point the system is enough functioning or 
too activated to induce a further up-regulation during the cognitive task. 
On the contrary, in dorsal hippocampus two-way ANOVA analysis revealed a significant effect 
only of the cognitive test (F1-49: 13.720, p<0.01), but not of the stress (F3-49: 1.249, p>0.05) and 
of the stressXtest interaction (F3-49: 1.496, p>0.05), with Arc being up-regulating only in no 
stress rats (+64%, p<0.01 vs no stress/Naïve) (fig. 37B). 
 
 
Fig. 37: Analysis of Arc mRNA levels in the prefrontal cortex (PFC) and dorsal hippocampus (dHip) of 
acutely stressed rats exposed to the novel object recognition test (NOR) 1h (restraint-1h), 4h (restraint-
4h) and 24h (restraint-24h) after the end of the challenge. The data, expressed as % of no stress/Naive 
rats (set al 100%), are the mean of at least 5 independent determinations ± SEM. * p<0.05, ** p<0.01, 
*** p<0.001 vs no stress/Naive; §§§ p<0.001 vs restraint-4h/Naive; $$$ p<0.001 vs restraint-24h/Naïve 
(two-way ANOVA with PLSD). 
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1.18.1.6 Effect of the cognitive test exposure after the acute restraint stress: focus on Gadd45b 
expression in rat prefrontal cortex and dorsal hippocampus 
In prefrontal cortex, two-way ANOVA results showed a significant effect of stress (F3-50: 8.089, 
p<0.001), of the cognitive test (F1-50: 92.221, p<0.001) and of stressXtest interaction (F3-50: 
8.884, p<0.001). Accordingly, the exposure to the behavioral test induced an up-regulation of 
Gadd45b mRNA levels in non-stressed rats (+116%, p<0.001 vs no stress/Naïve), in rats tested 
4hours (+133%, p<0.001 vs restraint-4h/Naïve) and 24 hours (+77%, p<0.001 vs restraint-
24h/Naïve) after the stress. 
However, one hour after the acute challenge we did not observed any further up-regulation 
induced by the NOR (: +5%, p>0.05 vs restraint-1h/Naïve) (fig. 38A). 
On the contrary, in dorsal hippocampus (fig. 38B), we found a different modulation of 
Gadd45b following the NOR task. Indeed, in line with previous findings (chapter 4.2, fig. 19B), 
the cognitive performance induced a significant increase of its mRNA levels (+63%, p<0.001 
vs no stress) in non-stressed rats, while the exposure to the test one hour after the acute 
challenge significant decreased Gadd45b expression (-28%, p<0.05 vs restraint-1h/Naïve), as 
confirmed by the two-way ANOVA analysis (test: F1-50: 4.169, p<0.05; stressXtest: F3-50: 
11.122, p<0.05).  
These results further support that the prefrontal cortex is the brain region mainly activated 
during the cognitive performance. Again, we did not find this increased activation compare to 
the “basal” condition in the restrain-1h group, as confirmation of the fact that the improvement 
in the cognitive performance found at this time point is due to the effect of the acute stress. 
 
Fig. 38: Analysis of Gadd45b mRNA levels in the prefrontal cortex (PFC) and dorsal hippocampus 
(dHip) of acutely stressed rats exposed to the novel object recognition test (NOR) 1h (restraint-1h), 4h 
(restraint-4h) and 24h (restraint-24h) after the end of the challenge. The data, expressed as % of no 
stress/Naive rats (set al 100%), are the mean of at least 5 independent determinations ± SEM. * p<0.05, 
*** p<0.001 vs no stress/Naive; # p<0.05 vs restraint-1h, §§§ p<0.001 vs restraint-4h/Naïve; $$$ 
p<0.001 vs restraint-24h/Naïve (two-way ANOVA with PLSD). 
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1.18.1.7 Effect of the cognitive test exposure after the acute restraint stress: focus on total Bdnf 
and Bdnf isoform IV expression in rat prefrontal cortex and dorsal hippocampus 
In prefrontal cortex, two-way ANOVA results showed a significant effect of stress (F3-48: 4.147, 
p<0.05) and of the cognitive test (F1-48: 29.815, p<0.001), with no significant stressXtest 
interaction (F3-48: 0.672, p>0.05) on total Bdnf expression. Accordingly, the behavioral test 
induced an up-regulation of total Bdnf mRNA levels in non-stressed rats (+83%, p<0.001 vs no 
stress/Naïve), in rats tested 4hours (+67%, p<0.01 vs restraint-4h/Naïve) and 24 hours (+52%, 
p<0.05 vs restraint-24h/Naïve) after the challenge (fig. 39A). 
Similar to what observed for the total form of the neurotrophin, Bdnf isoform IV was 
significantly modulated by stress (F3-50: 12.874, p<0.001) by the cognitive test (F1-50: 40.345, 
p<0.001) and by the stressXtest interaction (F3-50: 3.525, p<0.05). Indeed, as shown in figure 
39B, the test exposure significantly increased Bdnf isoform IV in no stress (+144%, p<0.001 vs 
no stress/Naïve), in restraint-4h (+45%, p<0.05 vs restraint-4h/Naïve) and in restraint-24h 
(+56%, p<0.01 vs restraint-24h/Naïve) groups.  
On the contrary, both for total Bdnf and for Bdnf isoform IV, one hour after the acute challenge 
we did not observed any further up-regulation induced by the cognitive test (total Bdnf: +27%, 
p>0.05 vs restraint-1h/Naïve; Bdnf isoform IV: +14%, p>0.05 vs restraint-1h/Naïve). 
In dorsal hippocampus we found a milder modulation due to both stress and cognitive test.  
For total Bdnf (fig. 39C) we observed a significant stressXtest interaction (F3-49: 3.093, p<0.05), 
with no effect of the stress (F3-49: 1.023, p>0.05) and of the test (F1-49: 2.579, p>0.05). The post 
hoc analysis, indeed, showed a significant increase of total Bdnf only in non-stress rats exposed 
to NOR (+50%, p<0.05 vs no stress/Naïve).  
On the contrary, Bdnf isoform IV was not modulated by the stress (F3-50: 0.659, p>0.05), by the 
test (F1-50: 0.346, p>0.05), with no significant stressXtest interaction (F3-50: 0.444, p>0.05) (fig. 
39D). 
These results suggest that the neurotrophin increased in the PFC may be implicated in the 
correct cognitive performance. Instead, as observed for Arc, the up-regulation induced by the 
acute stress per sè that is already present 1 hour later is sufficient to significantly improve the 
results in the behavioral test. 
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Fig. 39: Analysis of total Bdnf and Bdnf isoform IV mRNA levels in the prefrontal cortex (PFC) and 
dorsal hippocampus (dHip) of acutely stressed rats exposed to the novel object recognition test (NOR) 
1h (restraint-1h), 4h (restraint-4h) and 24h (restraint-24h) after the end of the challenge. The data, 
expressed as % of no stress/Naive rats (set al 100%), are the mean of at least 5 independent 
determinations ± SEM. * p<0.05, ** p<0.01, *** p<0.001 vs no stress/Naive; § p<0.05, §§ p<0.01 vs 
restraint-4h/Naive; $ p<0.05, $$ p<0.01 vs restraint-24h/Naïve (two-way ANOVA with PLSD). 
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1.18.2 Discussion  
In this study we found that exposure to acute stress positively acts on cognitive performance 
with a specific time profile. Moreover, at molecular level our results support that neuroplastic 
mechanisms play a fundamental role in working memory processes as well as in the 
improvement due to a single session of restraint stress. 
The role of stress in modulating learning and memory has been well described (Joels et al., 
2006), with different issues based on the type and length of stressors. Indeed, while chronic 
stress has detrimental effect on cognitive functions (McEwen and Sapolsky, 1995), acute stress 
may have a dual effect: it may improve memory or, when severe, it can impair it (Hains and 
Arnsten, 2008). In the field of adaptive response to stress, several studies have shown that stress, 
in close association with learning task, facilitated the memory consolidation (de Kloet et al., 
1999) and might be indispensable for the good learning (Sandi et al., 1997;Lupien et al., 2002). 
Here, we assessed the influence of one hour of acute restraint stress in modulating the cognitive 
performance measured 1 hour, 4 hours and 24 hours post challenge. We found that animals 
exposed to the restraint stress performed significantly better than non-stressed rats when 
examined 1 hour and four hours post-stress. This difference disappeared 24 hours following the 
challenge, indicating a transient effect of stress pre-exposure and the performance. In 
accordance, Yuen and colleagues demonstrated an enhanced working memory in the T-maze 
following 20 minutes of forced swim stress not only 4 hours but also 1 day after, whereas not 
48 hours later (Yuen et al., 2009). The discrepancy between the effect found 24 hours after the 
challenge may be due to the different stress used and to the diverse cognitive task employed. 
Additionally, others behavioral studies demonstrated that moderate acute stress facilitated 
classical fear conditioning (Shors et al., 1992). 
Then, in order to establish the molecular mechanisms set in motion by the acute stress, 
potentially involved in promoting the performance in the novel object recognition test, here we 
focused on neuronal activation and neuroplasticity. 
The immediate early gene Arc was highly enhanced by the restraint stress, in both prefrontal 
cortex and dorsal hippocampus, and this modulation last until 24 hours after the stress, 
suggesting a long-lasting activation driven by the challenge. However, the higher increase at 
time 1 hour, as the results obtained for the neuronal activity dependent gene Gadd45b at the 
same time point, in both the brain regions, suggested the possible implication of the IEGs in the 
behavioral results. Accordingly, in the PFC, the increase of total Bdnf and Bdnf isoform IV 
occurred rapidly after 1 hours of stress and it was transient, in line with the evidence the 
neurotrophin is enhanced by acute stimulations, thus being a part of a compensatory response 
to preserve brain homeostasis (Marmigere et al., 2003). Indeed, a short stress may trigger the 
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neurotrophin increase thus contributing to store information that could serve to prepare a 
response to a new stimulus. Furthermore, the fact that 4 and 24 hours post-stress the 
neurotrophins were not still increased may suggest that in the PFC the acute challenge enhance 
mainly short-time effect in the Bdnf-early response. Conversely in the dHip, total Bdnf was 
significantly modulated 1day post-stress, indicating a different brain region involvement in the 
fast stress response. On the contrary, Marmigere and colleagues found that short-time stress 
application (60 minutes) increased Bdnf in the whole hippocampus, whereas a longer time of 
stress (180 minutes) decreased it (Marmigere et al., 2003). Moreover, when we assessed the 
molecular outcome in the animals exposed to the NOR, we found that in the PFC the IEGs Arc 
and Gadd45b were significantly up-regulated in non-stressed rats and in animals tested 4 and 
24 hours post stress, in accordance with the evidence that the immediate early genes play a role 
in the neuroplastic mechanisms required for the memory consolidation processes (Robertson, 
1992;Dragunow, 1996;Tischmeyer and Grimm, 1999). Indeed, the inhibition of the 
hippocampal Arc protein expression impaired long-term potentiation as well as the long term 
memory (Guzowski et al., 1999), supporting the findings that the Arc-mediated improved 
plasticity we observed could be involved in the behavioral outcome obtained in this experiment.  
Similarly, the expression of both the total neurotrophin and Bdnf isoform IV was significantly 
enhanced in the cognitive task in non-stressed rats and in stressed rats tested in the NOR 4 and 
24 hours following the acute stress. Accordingly, it is known that neurotrophic factors are 
implicated in long term potentiation and that stress may modify cognitive function via 
regulation of Bdnf (Dragunow et al., 1993). 
The present findings suggest that acute restraint stress per sè was able to up-regulate the gene 
expression of different target up to 24 hours later in both the brain regions with a different time-
profile. Moreover, these increases were also observed after the NOR. 
Interestingly, one-hour after the restraint stress, when the improvement in the cognitive 
performance was major, we did not find a further regulation due to the test (compare to that 
caused by the stress) suggesting that starting the test with an already high level of these genes 
is enough to ameliorate the behavioral outcome. 
  
  105 
 
Summary and conclusions 
In conclusion, the results obtained during my PhD provide evidence, at preclinical level, about 
the effects of stress exposure at adulthood in contributing to the development of mood disorders. 
We used different experimental paradigms not only to investigate the molecular mechanisms 
contributing to the development of the depressive like-behavior, but also to identify pathways 
and systems related to remission and to relapse, which are critical aspects for the treatment of 
depressed patients. Moreover, we add knowledge on the molecular effect of the antipsychotic 
drug lurasidone, characterized by a multi-receptors profile, in the modulation of the stress-
induced alterations. 
We took advantage of the chronic mild stress paradigm, a well-established animal model of 
depression, to analyze the vulnerability to stress exposure and we demonstrated that 
independently from the susceptible and resilient phenotype, in term of anhedonia, all stressed 
rats developed cognitive deficits. These behavioral results suggested that the molecular systems 
underlying several pathological domains of MDD are probably different. In particular, we found 
that the cognitive dysfunctions were associated with the inability to activate the synthesis of 
new proteins specifically at synaptic levels in rat dorsal hippocampus, a key brain region for 
memory processes. More in details, we have shown that chronic stress interfered with the 
elongation phase of the protein synthesis, by preventing the activation of the NMDA-mTOR 
pathway, a fundamental step for the correct cognitive performance that we observed in non-
stressed animals (Calabrese et al., 2017). 
Furthermore, we provide further evidence of the involvement of the hypothalamic-pituitary-
adrenal axis, and in particular of the genomic and non-genomic effects of glucocorticoid 
receptor in the dorsal hippocampus, in the CMS-induced behavioral abnormalities. Indeed, we 
demonstrated that the activation of the GR nuclear signaling was associated with the correct 
cognitive performance whereas chronic stress exposure interfered with this mechanism, thus 
inhibiting the transcription of GR responsive genes involved in learning and memory processes. 
In addition, stress, by increasing the availability of GR at membrane levels, seems to direct 
preferentially the action of hormones more towards the non-genomic pathways, thus altering 
synaptic and mitochondrial signaling. 
Moreover, in a section of this thesis, we considered the implication of epigenetic mechanisms 
in the regulation of the HPA axis in the CMS-mediated behavioral deficits and we found that 
chronic stress exposure increased the DNA methylation of specific genes involved in the HPA 
axis signaling, thus interfering with their transcription, in rat prefrontal cortex. As an example, 
we found that 7 weeks of CMS increased the methylation status of the CGs in the glucocorticoid 
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responsive element on Gadd45b DNA sequence, underlying the inability of the glucocorticoid 
receptor to activate its downstream target. 
Furthermore, we showed that the effects of chronic stress exposure during adult life were 
persistent, with long-lasting consequences not only on epigenetics, with the GR responsive 
factors Gadd45b  and Sgk1 being hypermethylated also after the recovery, but also on 
mechanisms of neuronal plasticity, including the neurotrophic factor Bdnf, suggesting that not 
all the systems impaired by stress were restored during remission, thus representing some scars 
of vulnerability that, in turn, may promote the relapse to the pathology. 
Moreover, since a high percentage of depressed patients experience relapse, condition that may 
be due to the inability to correctly react to any external stimuli even when the recovery is 
achieved, we investigated the outcomes of a novel stressor exposure after the remission phase. 
In particular, we observed that the long-lasting effect of stress on Bdnf expression in prefrontal 
cortex interfered with the capability to react to a new challenge in the post stress period, 
suggesting the endurable detrimental consequence of chronic adversities. On the contrary, we 
found that the increased expression of activity-dependent genes, such as Arc, induced by an 
acute stress was not impaired by a previous exposure to CMS, indicating that different 
mechanisms control the persistent modifications induced by chronic stress.  
Conversely, the exposure to one hour of acute restraint stress improved cognitive function with 
a specific temporal profile. Indeed, we found that the challenge enhanced the performance one 
hour and four hours post the acute stressor. Interestingly we pointed out how this adaptive 
response was mediated by the induction of mechanisms of neuronal plasticity mainly in the rat 
prefrontal cortex. Indeed, we demonstrated that the increased expression of the activity 
dependent early genes and of Bdnf, due to the acute stress, were responsible for the behavioral 
outcome in the novel object recognition task, thus underlying their fundamental contribution in 
the memory performance.  
We underlined the ability of lurasidone in modulating the behavioral alterations induced by the 
CMS paradigm. Indeed, the drug was able to normalize the anhedonic phenotype, in line with 
our previous findings (Calabrese et al., 2016), and completely reverted the cognitive deficits 
due to chronic stress exposure. This result provides further support to the pro-cognitive effect 
of lurasidone, that may be mediated by its intrinsic activity as antagonist of the serotoninergic 
receptor 5HT-7, known to be important for learning and memory (Hedlund and Sutcliffe, 
2004;Thomas and Hagan, 2004). 
At molecular level, we highlighted the ability of this multi-receptor modulator drug in 
normalizing the anhedonic phenotype and the cognitive deficits by restoring the modification 
observed in the GR activity. In particular, lurasidone not only acted at genomic levels, but 
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exerted protective properties on the membrane GR pathways at both synaptic and mitochondrial 
levels, thus counteracting the stress-related abnormalities. Moreover, chronic lurasidone 
treatment was able to normalize DNA methylation changes produced by chronic stress, 
suggesting the potential of the drug to interfere with the epigenetic alterations produced by the 
adverse experiences.  
Conversely, if lurasidone treatment is interrupted during the rest period, the protective effect is 
lost, indicating that the continuation of the pharmacological administration even after the end 
of the stress phase, may avoid the possible rebound mechanisms set in motion by drug 
withdrawal. 
Indeed, it may be proposed that the extension of the treatment during the recovery could have 
a beneficial effect in preventing further relapses. However, when the stressed brain had to react 
to a new challenge following the stress and treatment washout, the administration of lurasidone 
in the pre-recovery period was able to counteract some alterations due to chronic stress, by 
facilitating the reaction to the new stimulus. In particular, with respect to the neurotrophic 
factor, the drug had the ability to enhance the transcription of the neurotrophin in rats previously 
stressed, indicating the protective efficacy of lurasidone in counteracting CMS-induced scars. 
In conclusion, the results obtained during my PhD program contribute to better understand the 
maladaptive and adaptive outcomes of stress exposure during adult life. We describe potential 
molecular mechanisms that contribute to different aspects and phases of stress-related 
disorders. In particular, we highlight the complexity of the changes contributing to the long-
lasting functional effects brought about by stress exposure that may, therefore, be relevant for 
specific domains of psychiatric disorders. In addition, even if the involvement of the 
glucocorticoid receptor in the development of psychiatric disorders is well established, we 
demonstrated, for the first time, the ability of lurasidone to counteract the detrimental 
consequence of chronic stress exposure, by modulating the HPA axis functioning, mechanisms 
by which the antipsychotic lurasidone may act as antidepressant.  
However, the use of one drug with a multi-receptor profile in a specific animal model of the 
pathology might be considered as a limitation of the study. It will be important to investigate 
drugs with different receptor profiles in order to establish the different effects on distinct 
functional domains affected by stress exposure.  
Furthermore, the employment of selected behavioral tests with a precise schedule allowed us to 
evaluate specific symptomatologic domains of stress-related disorders, although additional tests 
will be necessary to provide a more complete picture of the changes that may contribute to the 
risk of psychiatric disorders.  
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 All in all, our findings add new knowledge to the field of the pharmacological research for 
novel targets and approaches for the treatment of depression and stress-related disorders.  
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